

Supporting Information

Understanding the Regioselectivity of 5-Substituted 1*H*-Tetrazoles Alkylation

Guillaume Reynard, Julien Moisan-Labelle, Étienne Parent and Hélène Lebel*.

*Department of Chemistry and Center in Green Chemistry and Catalysis (CGCC), Université de Montréal,
P.O. Box 6128, Station Downtown, Montréal, QC H3C 3J7, Canada*

Table of Contents


General Information	S-2
Dinitrite Reagents Synthesis.....	S-2
Starting Material Synthesis	S-3
Procedure for the Optimization of the Continuous Flow Alkylation of 1<i>H</i>-Tz	S-4
Figure S1. Continuous Flow Reactor Set-up.....	S-4
Table S1. Optimization of the Continuous Flow Alkylation of 1<i>H</i>-Tz via Amine Diazotization	S-5
Table S2. Alkylation of Various Tetrazoles with Phenethylamine	S-5
Table S3. Alkylation of Various Tetrazoles with Benzylamine	S-5
Table S4. Alkylation of 5-(3,4-dinitrophenyl)-1<i>H</i>-tetrazole with Various Amines	S-6
General procedures.....	S-6
Characterization data	S-6
NMR Spectra	S-28

General Information

Analytical thin-layer chromatography was performed using 0.25 mm silica gel 60-F plates. Visualization of the developed chromatogram was performed by UV absorbance, cerium ammonium molybdate, or aqueous potassium permanganate. Flash chromatography was performed using silica gel (230–400 mesh) with the indicated solvent system. Infrared spectra are reported in reciprocal centimeters (cm^{-1}). Only the most important and relevant frequencies are reported. Chemical shifts for ^1H NMR spectra were recorded in parts per million with the solvent resonance as the reference CDCl_3 ($\delta = 7.26$ ppm) unless otherwise indicated. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintuplet, sx = sextet, sept = septet, m = multiplet and br = broad), coupling constant in Hz and integration. Chemical shifts for ^{13}C NMR spectra are recorded in parts per million using the central peak of CDCl_3 ($\delta = 77.16$ ppm) as the reference unless otherwise indicated. All ^{13}C NMR spectra were obtained with complete proton decoupling. All NMR yields were determined using quantitative ^1H NMR spectra using tetrachloroethane as an internal standard with a 10-sec relaxation time. High resolution mass spectra analysis was performed by the Centre régional de spectroscopie de masse de l'Université de Montréal.

Dinitrite Reagents Synthesis

1,3-Propanedinitrite and 1,3-(2,2-Dimethyl)propanedinitrite were synthesized according to previously reported methods.^{1,2} *DSC-TGA spectra of dinitrite reagents in a sealed stainless-steel crucible revealed an important, strong exothermic event from ~120 to 175 °C, with an important loss of mass and a significant modification of temperature setpoint, consistent with a decomposition. Heating dinitrite reagents concentrated or neat is thus not recommended, as autocatalytic decomposition may occur and overpressure might develop, due to the formation of gases. Distillation should also be avoided.*



2,2-Diethylpropane-1,3-diyl dinitrite. In a 100 mL round bottom flask with magnetic stirring bar, sodium nitrite (4.43 g, 64.3 mmol, 2.40 equiv) was dissolved in H_2O (15 mL) under ambient atmosphere. 2,2-diethyl-1,3-propanediol (3.54 g, 26.8 mmol, 1.00 equiv) was added and the solution was cooled to 0 °C. A solution of H_2SO_4 (4.89 mL, 64.3 mmol, 2.40 equiv) diluted in H_2O (15 mL) was added dropwise with an addition funnel over a period of 30 min. The reaction was stirred 60 min at 0 °C after the end of addition. The reaction was transferred in a separatory funnel and brine (15 mL) was added. The two layers were separated, and the organic layer was washed with brine, then dried over Na_2SO_4 . The title compound was isolated as a yellow liquid (4.94 g, 26.0 mmol, 97% yield). 2,2-diethylpropane-1,3-diyl dinitrite was stored on Na_2SO_4 at rt during few months without significant decomposition. ^1H NMR (300 MHz, CDCl_3) δ 4.56 (s, 4H), 1.38 (q, $J = 5.2$ Hz, 4H), 0.87 (t, $J = 7.5$ Hz, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 69.5, 40.7, 23.1, 7.0.




Cyclopropane-1,1-diylbis(methylene) dinitrite. In a 100 mL round bottom flask with magnetic stirring bar, sodium nitrite (4.49 g, 67.9 mmol, 2.40 equiv) was dissolved in H_2O (15 mL) under ambient atmosphere. Cyclopropane-1,1-diylmethanol (2.89 g, 28.3 mmol, 1.00 equiv) was added and the solution was cooled to 0 °C. A solution of H_2SO_4 (5.17 mL, 67.9 mmol, 2.40 equiv) diluted in H_2O (15 mL) was added dropwise with an addition funnel over a period of 30 min. The reaction was stirred 60 min at 0 °C after the end of addition. The reaction was transferred in a separatory funnel and brine (15 mL)

¹ G. Reynard, E.-M. Joseph-Valcin and H. Lebel, *Chem. Commun.*, 2020, **56**, 10938-10941.


² C. Audubert and H. Lebel, *Org. Lett.*, 2017, **19**, 4407-4410.

was added. The two layers were separated, and the organic layer was washed with brine, then dried over Na₂SO₄. The title compound was isolated as a bright orange liquid (4.40 g, 27.5 mmol, 97% yield). Cyclopropane-1,1-diylbis(methylene) dinitrite was stored on Na₂SO₄ in the fridge during few weeks without significant decomposition. ¹H NMR (300 MHz, CDCl₃) δ 4.66 (s, 4H), 0.73 (s, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 71.9, 20.9, 9.8.


Starting Material Synthesis




3-(Trimethylsilyl)prop-2-yn-1-amine. 3-(trimethylsilyl)prop-2-yn-1-amine was prepared from propargylamine, lithium bis(trimethylsilyl)amide, and chlorotrimethylsilane according to the literature procedure affording the hydrochloride salt.³ It was then dissolved in sat. NaHCO₃, extracted three times with CHCl₃. The combined organic layers were dried over Na₂SO₄, and concentrated under vacuum at room temperature. Distillation afforded the free base as a clear oil. ¹H NMR (400 MHz, CDCl₃) δ 3.43 (s, 2H), 1.31 (br.s., 2H), 0.16 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 107.5, 86.7, 32.5, 0.1.



2-(4-Nitrobenzyl)isoindoline-1,3-dione. 2-(4-nitrobenzyl)isoindoline-1,3-dione was prepared from 4-nitrobenzyl bromide according to literature procedure.⁴ ¹H NMR (500 MHz, CDCl₃) δ 8.18 (d, *J* = 8.8 Hz, 2H), 7.87 (dd, *J* = 5.5 Hz, 3.0 Hz, 2H), 7.75 (dd, *J* = 5.5 Hz, 3.1 Hz, 2H), 7.58 (d, *J* = 8.8 Hz, 2H), 4.93 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 167.9, 147.7, 143.4, 134.5, 132.0, 129.5, 124.1, 123.8, 41.0.



4-Nitrobenzylamine. 4-nitrobenzylamine was prepared from 2-(4-nitrobenzyl)isoindoline-1,3-dione according to literature procedure.⁵ ¹H NMR (500 MHz, CDCl₃) δ 8.19 (d, *J* = 8.6 Hz, 2H), 7.50 (d, *J* = 8.7 Hz, 2H), 4.00 (s, 2H), 1.50 (br.s., 2H); ¹³C NMR (125 MHz, CDCl₃) δ 150.7, 147.0, 127.8, 123.9, 45.9.



3,5-Dimethylbenzonitrile. 3,5-dimethylbenzonitrile was prepared from 1-bromo-3,5-dimethylbenzene according to literature procedure.⁶ ¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 2H), 7.21 (s, 1H), 2.35 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 139.1, 134.7, 129.8, 119.3, 21.1.


³ J. Derosa, A. L. Cantu, M. N. Boulous, M. L. O'Duill, J. L. Turnbull, Z. Liu, D. M. De La Torre, K. M. Engle, *J. Am. Chem. Soc.*, 2017, **139**, 5183-5193.

⁴ Y. Katsura, T. Tomishi, Y. Inoue, K. Sakane, Y. Matsumoto, C. Morinaga, H. Ishikawa, H. Takasugi, *J. Med. Chem.*, 2000, **43**, 3315-3321.

⁵ P. Liu, Y. Du, L. Song, J. Shen, Q. Li, *Bioorg. Med. Chem.*, 2015, **23**, 7079-7088.

⁶ J. Zanon, A. Klapars, S. L. Buchwald, *J. Am. Chem. Soc.*, 2003, **125**, 2890-2891.

Procedure for the Optimization of the Continuous Flow Alkylation of 1*H*-Tz



A 5 mL sample loop A was charged with a 0.1 M solution of the tetrazole (0.50 mmol, 1.00 equiv) in THF and a 0.25 M solution of the amine (1.25 mmol, 2.50 equiv). A 1 mL sample loop B was charged with a 1.6 M solution of the 1,3-(2,2-dimethyl)-propanedinitrite (0.800 mmol, 1.6 equiv). The solutions were prepared in a 10 mL gauge flask. The 2 loops were injected in the system with the calculated flowrate in a reactor at the desired temperature with a back-pressure regulator at 250 psi. When more than one 10 mL reactor was used, the reactors were connected head-to-head. After the desired residence time, the product was collected in an opened flask (25 mL collection volume).





Figure S1. Continuous Flow Reactor Set-up

Table S1. Optimization of the Continuous Flow Alkylation of 1*H*-Tz via Amine Diazotization

Entry	T (°C)	t (min)	V (mL)	1a yield	1a : 1b ratio
1	70	30	40	41%	76 : 24
2	100	30	40	40%	74 : 26
3	100	15	40	43%	77 : 23
4	100	15	20	45%	78 : 22
5	120	30	40	52%	79 : 21
6	120	15	20	49%	79 : 21
7	120	5	20	47%	78 : 22
8	120	60	20	45%	80 : 20
9	140	15	20	57%	78 : 22
10	140	5	10	42%	78 : 22
11	160	15	20	46%	78 : 22
12	160	5	20	46%	79 : 21


Notes: Reactions were performed on a 1 mmol scale. PFA tubings were used for temperature up to 120 °C. For temperature of 140 °C and above, stainless still reactors were used. Both reactors were tested at 120 °C without a significant modification of the yield. Yields were calculated by NMR using 1,1,2,2-tetrachloroethane as the internal standard.

Table S2. Alkylation of Various Tetrazoles with Phenethylamine




Entry	Ar	Yield (2,5-Tz)	Yield (1,5-Tz)	Ratio	substrate
1	3,5-diMePh	59%	22%	73 : 27	35
2	Ph	70%	17%	80 : 20	36
3	3-BrPh	77%	18%	81 : 19	37
4	3-NO ₂ Ph	73%	12%	86 : 14	38
5	4-NO ₂ Ph	80%	8%	91 : 9	39
6	3,5-diNO ₂ Ph	87%	Not isolated	93 : 7	40

Table S3. Alkylation of Various Tetrazoles with Benzylamine



Entry	Ar	Yield (2,5-Tz)	Yield (1,5-Tz)	Ratio	substrate
1	3,5-diMePh	55%	24%	70 : 30	41
2	Ph	59%	24%	71 : 29	6
3	3-BrPh	65%	26%	71 : 29	42
4	3-NO ₂ Ph	66%	24%	73 : 27	43
5	4-NO ₂ Ph	67%	18%	79 : 31	44
6	3,5-diNO ₂ Ph	70%	22%	76 : 24	45

Table S4. Alkylation of 5-(3,4-dinitrophenyl)-1H-tetrazole with Various Amines



Entry	R	Yield (2,5-Tz)	Yield (1,5-Tz)	Ratio	Substrate
1	(S)-1-phenylethyl	50%	19%	72 : 28	46
2	4-OMePhCH ₂	64%	24%	73 : 27	47
4	4-NO ₂ PhCH ₂	69%	14%	83 : 17	48
6	Me	86%	6%	94 : 6	49

General procedures

General procedure A for the alkylation of 5-monosubstituted tetrazoles


In a round bottom flask with a magnetic stirring bar, the 5-monosubstituted tetrazole (0.500 mmol, 1.00 equiv) was suspended in EtOAc (4 mL). The resulting suspension was stirred at room temperature. 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) was added, followed by the amine (1.25 mmol, 2.50 equiv.). The flask was placed in an oil bath, and the mixture was heated to reflux for 16 hours. The solvent was removed under reduced pressure, and the crude mixture was purified by flash chromatography.

General procedure B for the sequential one-pot cycloaddition-diazotisation reaction

In a round bottom flask with a magnetic stirring bar, the nitrile (0.500 mmol, 1.00 equiv) was diluted in toluene (1.5 mL). The resulting mixture was stirred at room temperature. Dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv) was added, followed by azidotrimethylsilane (0.099 mL, 0.750 mmol, 1.50 equiv). The flask was placed in an oil bath, and the mixture was heated to reflux for 4 h (procedure **B1**) or 16 hours (procedure **B2**). The mixture was cooled to room temperature, and toluene (2.5 mL) was added. 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) was added, followed by the amine (1.25 mmol, 2.50 equiv.). The flask was placed in an oil bath, and the mixture was heated to reflux for 16 hours. The mixture was stirred at room temperature. The solvent was removed under reduced pressure, and the crude mixture was purified by flash chromatography.

Characterization data

The synthesis of 2,5-Tz **1a**, **2**, **3a**, **4**, **6a**, **8a**, **9a**, **10a**, **11**, **13a**, **15**, **16**, **18a**, **19a**, **20a**, **23**, **24**, **31**, **32a**, **33a**, **37a**, **39a** and **49a** has been previously described.⁷




2-Benzyl-5-(4-bromophenyl)-2H-tetrazole (**1a**) and 1-benzyl-5-(4-bromophenyl)-1H-tetrazole (**1b**).

The title compounds were prepared according to the general procedure **A** using 5-(4-bromophenyl)-1H-tetrazole (113 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv) and 1,3-

⁷ G. Reynard and H. Lebel, *J. Org. Chem.*, 2021, **86**, 12452-12459.


(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10%, then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **1a** (112 mg, 0.36 mmol, 71% yield) was isolated as a white solid as previously reported.⁷ *R*_f 0.53 (20% EtOAc/hexanes); *mp* 103-107 °C (litt. 105-107 °C);⁸ ¹H NMR (400 MHz, CDCl₃) δ 8.01 (dt, *J* = 8.7 Hz, 2.1 Hz, 2H), 7.60 (dt, *J* = 8.7 Hz, 2.0 Hz, 2H), 7.45-7.34 (m, 5H), 5.80 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 164.8, 133.3, 132.2, 129.2, 128.6, 128.5, 126.5, 124.8, 57.1. Tetrazole **1b** (36.8 mg, 0.12 mmol, 23% yield) was isolated as a white solid. Spectral data matched those reported in the literature.⁸ *R*_f 0.28 (20% EtOAc/hexanes); *mp* 92-94 °C; ¹H NMR (300 MHz, CDCl₃) δ 87.64 (d, *J* = 9 Hz, 2H), 7.45 (d, *J* = 9 Hz, 2H), 7.37-7.34 (m, 3H), 7.17-7.12 (m, 2H), 5.61 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 154.0, 133.8, 132.7, 130.4, 129.4, 129.1, 127.2, 126.3, 122.8, 51.6.

The title compounds were also prepared according to the general procedure **B1** using 4-bromobenzonitrile (91.0 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step) leading to tetrazole **1a** (102 mg, 0.324 mmol, 65% yield) as a white solid and tetrazole **1b** (37.8 mg, 0.120 mmol, 24% yield) as a white solid.



2-Benzyl-5-(3-(trifluoromethyl)phenyl)-2H-tetrazole (3a) and 1-benzyl-5-(3-(trifluoromethyl)phenyl)-1H-tetrazole (3b). The title compounds were prepared according to the general procedure **A** using 5-(3-(trifluoromethyl)phenyl)-1H-tetrazole (107 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **3a** (85.1 mg, 0.36 mmol, 72% yield) was isolated as a white solid as previously reported.⁷ *R*_f 0.54 (20% EtOAc/hexanes); *mp* 69-74 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 8.33 (d, *J* = 7.8 Hz, 1H), 7.71 (d, *J* = 7.8 Hz, 1H), 7.60 (t, *J* = 7.8 Hz, 1H), 7.46-7.33 (m, 5H), 5.82 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 133.2, 131.5 (q, *J* = 32.8 Hz), 130.1 (d, *J* = 0.8 Hz), 129.6, 129.2, 128.6, 128.4, 128.0, 127.0 (q, *J* = 3.7 Hz), 123.9 (q, *J* = 3.9 Hz), 123.9 (d, *J* = 272.4 Hz), 57.1; ¹⁹F NMR (375 MHz, CDCl₃) δ 62.82 (s).

Tetrazole **3b** (42.6 mg, 0.14 mmol, 28% yield) was isolated as a pale-yellow oil. *R*_f 0.24 (20% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.84-7.77 (m, 3H), 7.64 (t, *J* = 8.1 Hz, 1H), 7.40-7.32 (m, 3H), 7.19-7.13 (m, 2H), 5.64 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 153.6, 133.6, 132.3, 131.9 (d, *J* = 33.2 Hz), 131.4, 130.0, 129.2, 128.1 (q, *J* = 3.6 Hz), 127.3, 126.0 (q, *J* = 3.6 Hz), 124.8, 123.7 (d, *J* = 272.7 Hz), 51.9; ¹⁹F NMR (375 MHz, CDCl₃) δ 62.93 (s); FTIR (cm⁻¹) (neat) 3200-2800, 1498, 1332, 1125, 747, 725, 697; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₂F₃N₄Na 305.1009, found 305.1008.




4-(2-Methyl-2H-tetrazol-5-yl)phenol (5a) and 4-(1-methyl-1H-tetrazol-5-yl)phenol (5b). The title compounds were prepared according to the general procedure **A** using 4-(1H-tetrazol-5-yl)phenol (81.1


⁸ Y.-J. Ding, Y. Li, S.-Y. Dai, Q. Lan, X.-S. Wang, *Org. Biomol. Chem.*, 2015, **13**, 3198-3201.

mg, 0.500 mmol, 1.00 equiv), methylamine (0.625 ml, 1.25 mmol, 2.50 equiv, 2 M in THF) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 30% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **5a** (38.7 mg, 0.22 mmol, 44% yield) was isolated as a white solid. Spectral data matched those reported in the literature.⁹ *R_f* 0.53 (50% EtOAc/hexanes); *mp* 197-202 °C (litt. 210-212 °C);⁹ ¹H NMR (400 MHz, acetone-d₆) δ 8.85-8.81 (br. s., 1H), 7.96 (dt, *J* = 8.8 Hz, 2.4 Hz, 2H), 6.99 (dt, *J* = 8.8 Hz, 2.3 Hz, 2H), 4.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.2, 160.6, 129.4, 120.5, 117.1, 40.1.

Tetrazole **5b** (10.6 mg, 0.06 mmol, 12% yield) was isolated as a pale-yellow sticky oil. Spectral data matched those reported in the literature.¹⁰ *R_f* 0.48 (50% EtOAc/hexanes); ¹H NMR (400 MHz, dms_o-d₆) δ 10.18 (br. s., 1H), 7.70 (d, *J* = 8.8 Hz, 2H), 6.97 (d, *J* = 8.7 Hz, 2H), 4.13 (s, 3H); ¹³C NMR (100 MHz, dms_o-d₆) δ 159.9, 153.9, 130.3, 115.9, 114.3, 35.0.



6a



6b

2-Benzyl-5-phenyl-2H-tetrazole (6a) and 1-benzyl-5-phenyl-1H-tetrazole (6b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **6a** (85.1 mg, 0.36 mmol, 72% yield) was isolated as a white solid as previously reported.⁷ *R_f* 0.57 (20% EtOAc/hexanes); *mp* 88-90 °C (litt. 90-92 °C);¹² ¹H NMR (400 MHz, CDCl₃) δ 8.19-8.11 (m, 2H), 7.51-7.44 (m, 3H), 7.44-7.32 (m, 5H), 5.80 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 133.5, 130.4, 129.1, 129.0, 128.9, 128.5, 127.5, 127.0, 56.9.


Tetrazole **6b** (30.7 mg, 0.13 mmol, 26% yield) was isolated as a pale-yellow oil. Spectral data matched those reported in the literature.¹¹ *R_f* 0.23 (20% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.61-7.53 (m, 3H), 7.52-7.46 (m, 2H), 7.38-7.31 (m, 3H), 7.18-7.11 (m, 2H), 5.61 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 154.8, 134.0, 131.5, 129.31, 129.29, 129.0, 128.9, 127.3, 123.9, 51.5.

The title compounds were also prepared according to the general procedure **B1** using benzonitrile (0.516 mL, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step) leading to tetrazole **6a** (70.0 mg, 0.296 mmol, 59% yield) as a white solid and tetrazole **6b** (28.0 mg, 0.12 mmol, 24% yield) as a clear oil.

⁹ S. Graßmann, B. Sadek, X. Ligneau, S. Elz, C. R. Ganellin, J.-M. Arrang, J.-C. Schwartz, H. Stark, W. Schunack, *Eur. J. Pharm. Sci.* **2002**, *15*, 367-378.

¹⁰ A. Xie, Q. Zhang, Y. Liu, L. Feng, X. Hu, W. Dong, *J. Heterocycl. Chem.* **2015**, *52*, 1483-1487.


¹¹ K. Livingstone, S. Bertrand, C. Jamieson, *J. Org. Chem.* **2020**, *85*, 7413-7423.



2-(3-Chlorobenzyl)-5-phenyl-2H-tetrazole (7a) and 1-(3-chlorobenzyl)-5-phenyl-1H-tetrazole (7b).


The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), 3-chlorobenzylamine (0.153 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **7a** (82.6 mg, 0.31 mmol, 61% yield) was isolated as a clear oil. *R_f* 0.48 (20% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 8.18-8.11 (m, 2H), 7.52-7.45 (m, 3H), 7.41 (s, 1H), 7.36-7.27 (m, 3H), 5.77 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 165.7, 135.2, 135.0, 130.5, 130.4, 129.3, 129.0, 128.6, 127.3, 127.0, 126.6, 56.4; FTIR (cm⁻¹) (neat) 3200-2800, 1600, 1472, 1404, 1079, 775, 734, 695; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₂ClN₄ 271.0745, found 271.0740.

Tetrazole **7b** (23.0 mg, 0.085 mmol, 17% yield) was isolated as a pale-yellow oil. *R_f* 0.18 (20% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.61-7.49 (m, 5H), 7.35-7.25 (m, 2H), 7.15 (s, 1H), 7.02 (d, *J* = 7.1 Hz, 1H), 5.58 (s, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 154.9, 135.8, 135.3, 131.7, 130.6, 129.4, 129.2, 128.9, 127.5, 125.4, 123.6, 50.8; FTIR (cm⁻¹) (neat) 3200-2800, 1600, 1448, 759, 731, 691; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₁N₄Na 293.0564, found 293.0561.



2-Methyl-5-phenyl-2H-tetrazole (8a) and 1-methyl-5-phenyl-1H-tetrazole (8b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), methylamine (0.625 ml, 1.25 mmol, 2M solution in THF, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (3.35 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 30% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **8a** (57.6 mg, 0.36 mmol, 72% yield) was isolated as a white solid as previously reported.⁷ *R_f* 0.53 (25% EtOAc/hexanes); *mp* 49-52 °C (litt: 50-52 °C);¹⁴ ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.10 (m, 2H), 7.51-7.44 (m, 3H), 4.39 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.39, 130.4, 129.0, 127.5, 126.9, 39.6.

Tetrazole **8b** (17.0 mg, 0.11 mmol, 21% yield) was isolated as a white solid. Spectral data matched those reported in the literature.¹² *R_f* 0.51 (50% EtOAc/hexanes); *mp* 101-105 °C (litt. 100-101 °C);¹² ¹H NMR (400 MHz, CDCl₃) δ 7.76-7.69 (m, 2H), 7.61-7.53 (m, 3H), 4.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 154.6, 131.4, 129.4, 128.8, 123.9, 35.1.




3-(5-Phenyl-2H-tetrazol-2-yl)propan-1-ol (9a) and 3-(5-phenyl-1H-tetrazol-1-yl)propan-1-ol (9b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), 3-aminopropan-1-ol (0.099 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-

¹² K. Ishihara, T. Shioiri, M. Matsugi, *Org. Lett.* **2020**, 22, 6244-6247.


dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 50% then 300 mL 75% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **9a** (74.5 mg, 0.37 mmol, 73% yield) was isolated as a clear oil as previously reported.⁷ R_f 0.56 (75% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.10-8.05 (m, 2H), 7.46-7.39 (m, 3H), 4.78 (t, J = 6.9 Hz, 2H), 3.70 (t, J = 5.9 Hz, 2H), 3.31-3.25 (br.s., 1H), 2.25 (qn, J = 6.4 Hz, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 165.0, 130.4, 128.9, 127.2, 126.7, 58.7, 50.1, 31.9; **FTIR** (cm^{-1}) (neat) 3600-3200, 3200-2800, 1611, 1530, 1450, 1044; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{10}\text{H}_{13}\text{N}_4\text{O}$ 205.1084, found 205.1082.

Tetrazole **9b** (24.5 mg, 0.12 mmol, 24% yield) was isolated as a clear oil. R_f 0.25 (75% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.75-7.71 (m, 2H), 7.62-7.55 (m, 3H), 4.60 (t, J = 6.9 Hz, 2H), 3.71 (q, J = 5.3 Hz, 2H), 2.21 (qn, J = 6.3 Hz, 2H), 1.61 (br. t, J = 4.7 Hz, 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 154.7, 131.4, 129.5, 128.9, 124.1, 58.9, 45.0, 32.1; **FTIR** (cm^{-1}) (neat) 3600-3200, 3200-2800, 1609, 1536, 1470, 1060, 779, 736, 697; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{10}\text{H}_{13}\text{N}_4\text{O}$ 205.1084, found 205.1081.



4-(5-Phenyl-2H-tetrazol-2-yl)butan-1-ol (10a) and 4-(5-phenyl-1H-tetrazol-1-yl)butan-1-ol (10b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), 4-amino-1-butanol (0.115 mL, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in CHCl_3 (4 mL). The crude mixture was purified by flash chromatography (300 mL 50% then 300 mL 80% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **10a** (78.6 mg, 0.36 mmol, 72% yield) was isolated as a clear oil as previously reported.⁷ R_f 0.46 (80% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.15-8.11 (m, 2H), 7.51-7.43 (m, 3H), 4.70 (t, J = 7.0 Hz, 2H), 3.71 (t, J = 6.2 Hz, 2H), 2.17 (quint., J = 7.3 Hz, 2H), 1.84-1.76 (br.s., 1H), 1.68-1.60 (m, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 165.2, 130.4, 129.0, 127.5, 126.9, 61.9, 53.1, 29.4, 26.1; **FTIR** (cm^{-1}) (neat) 3600-3200, 3100-2800, 1469, 1536, 1609, 1062, 697, 736; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{11}\text{H}_{15}\text{N}_4\text{O}$ 219.1240, found 219.1238.


Tetrazole **10b** (16.4 mg, 0.075 mmol, 15% yield) was isolated as a pale-yellow oil; R_f 0.28 (80% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.69-7.66 (m, 2H), 7.62-7.54 (m, 3H), 4.48 (t, J = 7.3 Hz, 2H), 3.66 (t, J = 5.8 Hz, 2H), 2.06 (quint., 7.5 Hz, 2H), 1.62-1.55 (m, 2H), 1.45-1.39 (br.s., 1H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 154.5, 131.4, 129.5, 128.9, 124.2, 61.9, 48.0, 29.3, 26.6; **FTIR** (cm^{-1}) (neat) 3600-3200, 3100-2800, 1449, 1539, 1611, 1046, 692, 731; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{11}\text{H}_{15}\text{N}_4\text{O}$ 219.1240, found 219.1237.




5-Phenyl-2-(3-(trimethylsilyl)prop-2-yn-1-yl)-2H-tetrazole (12a) and 5-phenyl-1-(3-(trimethylsilyl)prop-2-yn-1-yl)-1H-tetrazole (12b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), 3-(trimethylsilyl)prop-2-yn-1-amine (159 mg, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 5% then 300 mL 20% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **12a** (43.6 mg,

0.17 mmol, 34% yield) was isolated as a pale-yellow oil. R_f 0.64 (20% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.19-8.15 (m, 2H), 7.52-7.46 (m, 3H), 5.44 (s, 2H), 0.19 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 165.6, 130.6, 129.0, 127.3, 127.1, 94.9, 93.4, 43.7, -0.3; **FTIR** (cm^{-1}) (neat) 3100-2800, 2190, 1530, 1450, 1250, 732, 693; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{17}\text{N}_4\text{Si}$ 257.1217, found 257.1216.

Tetrazole **12b** (17.9 mg, 0.070 mmol, 14% yield) was isolated as a pale-yellow oil. R_f 0.29 (20% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.90-7.86 (m, 2H), 7.62-7.55 (m, 3H), 5.22 (s, 2H), 0.14 (s, 9H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 154.4, 131.6, 129.4, 129.0, 123.6, 95.9, 93.9, 39.1, -0.4; **FTIR** (cm^{-1}) (neat) 3100-2800, 2190, 1610, 1537, 1462, 1250, 731, 695; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{17}\text{N}_4\text{Si}$ 257.1217, found 257.1220.




13a




13b

2-Isopropyl-5-phenyl-2H-tetrazole (13a) and 1-isopropyl-5-phenyl-1H-tetrazole (13b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), isopropylamine (0.107 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **13a** (64.0 mg, 0.34 mmol, 68% yield) was isolated as a pale-yellow oil as previously reported.⁷ R_f 0.39 (10% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.18-8.12 (m, 2H), 7.52-7.41 (m, 3H), 5.11 (hept, J = 6.7 Hz, 1H), 1.70 (d, J = 6.7 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.9, 130.2, 128.9, 127.8, 126.9, 56.7, 22.3.

Tetrazole **13b** (25.4 mg, 0.14 mmol, 27% yield) was isolated as a pale-yellow oil. Spectral data matched those reported in the literature.¹³ R_f 0.32 (25% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.64-7.53 (m, 5H), 4.77 (hept, J = 6.7 Hz, 1H), 2.50 (d, J = 6.7 Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 153.7, 131.3, 129.4, 129.0, 124.5, 51.3, 23.1.



14a




14b

2-Cyclopentyl-5-phenyl-2H-tetrazole (14a) and 1-cyclopentyl-5-phenyl-1H-tetrazole (14b). The title compounds were prepared according to the general procedure **A** using 5-phenyl-1H-tetrazole (73.1 mg, 0.500 mmol, 1.00 equiv), cyclopentylamine (0.123 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **14a** (47.7 mg, 0.22 mmol, 45% yield) was isolated as a pale-yellow oil. R_f 0.68 (25% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.15 (dd, J = 7.9 Hz, 1.8 Hz, 2H), 7.51-7.43 (m, 3H), 5.26 (quint, J = 6.6 Hz, 1H), 2.28 (q, J = 6.5 Hz, 4H), 2.05-1.93 (m, 2H), 1.84-1.72 (m, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 164.9, 130.2, 127.8, 126.9, 65.1, 33.1, 24.5; **FTIR** (cm^{-1}) (neat) 3200-2800, 1528, 1465, 1449, 733, 694; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{12}\text{H}_{15}\text{N}_4$ 215.1291, found 215.1296.

Tetrazole **14b** (11.5 mg, 0.054 mmol, 11% yield) was isolated as a light-brown sticky oil. R_f 0.33 (25% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.66-7.61 (m, 2H), 7.59-7.52 (m, 3H), 4.86 (quint, J = 6.9 Hz, 1H), 2.19 (q, J = 6.5 Hz, 4H), 2.12-2.01 (m, 2H), 1.79-1.69 (m, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.2,


¹³ A. O. Koren, P. N. Gaponik, V. A. Ostrovskii, *Int. J. Chem. Kinet.* **1993**, 25, 1043-1051.

131.2, 129.3, 129.1, 124.6, 59.6, 34.0, 24.8; **FTIR** (cm⁻¹) (neat) 3200-2800, 1533, 1467, 1454, 737, 697; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₂H₁₅N₄ 215.1291, found 215.1291.




2-Benzyl-5-(5-chlorothiophen-2-yl)-2H-tetrazole (17a) and 1-benzyl-5-(5-chlorothiophen-2-yl)-1H-tetrazole (17b). The title compounds were prepared according to the general procedure **A** using 5-(5-chlorothiophen-2-yl)-1H-tetrazole (93.3 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.147 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **17a** (92.6 mg, 0.34 mmol, 67% yield) was isolated as a white solid. **R_f** 0.35 (10% EtOAc/hexanes); **mp** 71-76 °C; **¹H NMR** (400 MHz, CDCl₃) δ 7.55 (d, *J* = 3.9 Hz, 1H), 7.42-7.35 (m, 5H), 6.94 (d, *J* = 3.9 Hz, 1H), 5.76 (s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 160.8, 133.1, 133.0, 129.21, 129.20, 128.6, 127.7, 127.3, 127.2, 57.0; **FTIR** (cm⁻¹) (neat) 3200-2800, 1571, 1488, 1457, 1068, 749, 719, 695; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₂H₁₀N₄S 277.0309, found 277.0308.

Tetrazole **17b** (44.2 mg, 0.16 mmol, 32% yield) was isolated as a sticky pale-yellow oil. **R_f** 0.42 (25% EtOAc/hexanes); **¹H NMR** (400 MHz, CDCl₃) δ 7.42-7.34 (m, 3H), 7.20 (d, *J* = 3.9 Hz, 1H), 7.18-7.13 (m, 2H), 6.96 (d, *J* = 4.0 Hz, 1H), 5.73 (s, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 149.1, 136.1, 133.4, 129.7, 129.5, 129.1, 127.6, 126.9, 122.7, 51.6; **FTIR** (cm⁻¹) (neat) 3200-2800, 1607, 1492, 1449, 1073, 725, 692; **HRMS** (ESI-TOF) m/z: [M+Na]⁺ Calcd for C₁₂H₉N₄S 299.0129, found 299.0126.




3-(5-(5-Chlorothiophen-2-yl)-2H-tetrazol-2-yl)propan-1-ol (18a) and 3-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)propan-1-ol (18b). The title compound was prepared according to the general procedure **A** using 5-(5-chloro-2-thienyl)-1H-tetrazole (93.3 mg, 0.500 mmol, 1.00 equiv), 3-amino-1-propanol (0.101 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 50% then 300 mL 75% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **18a** (93.0 mg, 0.38 mmol, 76% yield) was isolated as a pale-yellow oil as previously reported.⁷ **R_f** 0.52 (75% EtOAc/hexanes); **¹H NMR** (500 MHz, CDCl₃) δ 7.49 (d, *J* = 3.9 Hz, 1H), 6.90 (d, *J* = 3.9 Hz, 1H), 4.75 (t, *J* = 6.9 Hz, 2H), 3.69 (t, *J* = 5.7 Hz, 2H), 3.02 (br.s., 1H), 2.23 (qn, *J* = 6.4 Hz, 2H); **¹³C NMR** (125 MHz, CDCl₃) δ 160.2, 132.9, 127.4, 127.2, 127.1, 58.6, 50.2, 31.8.; **FTIR** (cm⁻¹) (neat) 3600-3200, 3200-2800, 1575, 1485, 1415, 1058, 1032, 1007; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₈H₁₀ClN₄OS 245.0258, found 245.0262.

Tetrazole **18b** (26.9 mg, 0.11 mmol, 22% yield) was isolated as a clear oil. **R_f** 0.21 (75% EtOAc/hexanes); **¹H NMR** (400 MHz, CDCl₃) δ 7.53 (d, *J* = 4.0 Hz, 1H), 7.04 (d, *J* = 4.0 Hz, 1H), 4.67 (t, *J* = 7.1 Hz, 2H), 5.30 (q, *J* = 5.3 Hz, 2H), 2.28-2.19 (m, 3H); **¹³C NMR** (100 MHz, CDCl₃) δ 148.8, 135.9, 129.5, 127.7, 122.9, 58.6, 45.4, 31.8; **FTIR** (cm⁻¹) (neat) 3600-3200, 3200-2800, 1576, 1490, 1403, 1053, 1041, 1001; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₈H₁₀ClN₄OS 245.0258, found 245.0257.




8-(5-(5-Chlorothiophen-2-yl)-2H-tetrazol-2-yl)octan-1-ol (19a) and 8-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)octan-1-ol (19b). The title compound was prepared according to the general procedure **A** using 5-(5-chloro-2-thienyl)-1H-tetrazole (93.3 mg, 0.500 mmol, 1.00 equiv), 8-amino-1-octanol (0.210 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 40% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **19a** (120.0 mg, 0.38 mmol, 76% yield) was isolated as a pale-yellow oil as previously reported.⁷ R_f 0.48 (50% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.50 (d, J = 3.9 Hz, 1H), 6.90 (d, J = 3.9 Hz, 1H), 4.54 (t, J = 7.2 Hz, 2H), 3.55 (t, J = 6.7 Hz, 2H), 2.38 (br.s., 1H), 1.96 (qn, J = 6.9 Hz, 2H), 1.53-1.44 (m, 2H), 1.34-1.21 (m, 8H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 160.1, 132.6, 127.6, 127.1, 126.9, 62.6, 53.3, 32.6, 29.2, 29.1, 28.8, 26.2, 25.6; **FTIR** (cm^{-1}) (neat) 3600-3200, 3200-2800, 1576, 1486, 1034, 1007; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{20}\text{ClN}_4\text{OS}$ 315.1041, found 315.1046.

Tetrazole **19b** (28.6 mg, 0.91 mmol, 18% yield) was isolated as a clear oil. R_f 0.27 (50% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.40 (d, J = 4.0 Hz, 1H), 7.06 (d, J = 4.0 Hz, 1H), 4.48 (t, J = 7.4 Hz, 2H), 3.62 (t, J = 6.6 Hz, 2H), 1.95 (qn, J = 7.4 Hz, 2H), 1.54 (qn, J = 6.8 Hz, 2H), 1.46 (br.s., 1H), 1.40-1.27 (m, 8H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 148.6, 135.7, 129.3, 127.6, 123.0, 63.0, 48.5, 32.7, 29.5, 29.2, 29.0, 26.4, 25.7; **FTIR** (cm^{-1}) (neat) 3600-3200, 3200-2800, 1577, 1491, 1056, 1017, 805; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{20}\text{ClN}_4\text{OS}$ 315.1041, found 315.1043.




4-(2-Phenethyl-2H-tetrazol-5-yl)pyridine (20a) and 4-(1-phenethyl-1H-tetrazol-5-yl)pyridine (20b). The title compounds were prepared according to the general procedure **A** using 5-(4-pyridyl)-1H-tetrazole (73.6 mg, 0.500 mmol, 1.00 equiv), phenethylamine (0.157 ml, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 50% then 300 mL 80% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **20a** (106 mg, 0.42 mmol, 84% yield) was isolated as an off-white solid as previously reported.⁷ R_f 0.38 (50% EtOAc/hexanes); mp 60-69 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.75 (d, J = 5.6 Hz, 2H), 7.99 (d, J = 5.6 Hz, 2H), 7.33-7.21 (m, 3H), 7.18 (d, J = 7.2 Hz, 2H), 4.90 (t, J = 7.6 Hz, 2H), 3.37 (t, J = 7.6 Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 163.1, 150.7, 136.2, 134.8, 129.0, 128.7, 127.3, 120.8, 54.5, 35.7; **FTIR** (cm^{-1}) (neat) 3200-2800, 1611, 1497, 1457, 753, 716, 699; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{14}\text{N}_5$ 252.1244, found 252.1237.

Tetrazole **20b** (19.0 mg, 0.08 mmol, 15% yield) was isolated as a pale-yellow oil. R_f 0.21 (75% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.68 (d, J = 5.6 Hz, 2H), 7.24-7.15 (m, 3H), 7.08 (d, J = 5.6 Hz, 2H), 6.86 (d, J = 6.7 Hz, 2H), 4.65 (t, J = 6.7 Hz, 2H), 3.26 (t, J = 6.7 Hz, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 153.0, 150.7, 135.9, 131.8, 129.2, 128.8, 127.7, 122.7, 49.7, 36.4; **FTIR** (cm^{-1}) (neat) 3200-2800, 1683, 1609, 1496, 1454, 751, 701; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{14}\text{N}_5$ 252.1244, found 252.1243.



21a




21b

2-(2-Benzyl-2H-tetrazol-5-yl)pyridine (21a) and 2-(1-benzyl-1H-tetrazol-5-yl)pyridine (21b). The title compounds were prepared according to the general procedure **A** using 2-(1H-tetrazol-5-yl)pyridine (73.6 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 30% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **21a** (51.0 mg, 0.22 mmol, 41% yield) was isolated as a yellow solid. R_f 0.27 (50% EtOAc/hexanes); mp 70–76 °C; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.76–8.72 (m, 1H), 8.20 (d, $J=8$ Hz, 1H), 7.80 (td, $J=8$ Hz, 2H, 1H), 7.45–7.39 (m, 2H), 7.37–7.29 (m, 4H), 5.83 (s, 2H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 165.1, 150.3, 146.8, 137.1, 133.1, 129.1, 128.6, 124.9, 122.5, 57.1; **FTIR** (cm^{-1}) (neat) 3200–2800, 1593, 1497, 1456, 1043, 729, 711, 693; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{12}\text{N}_5$ 238.1087, found 238.1080.


Tetrazole **21b** (66.0 mg, 0.28 mmol, 52% yield) was isolated as a bright yellow oil. Spectral data matched those reported in the literature.¹⁴ R_f 0.48 (50% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.76–8.73 (m, 1H), 8.34 (dt, $J=8$ Hz, 1 Hz, 1H), 7.88 (td, $J=8$ Hz, 2H), 7.46–7.42 (m, 1H), 7.37–7.33 (m, 2H), 7.31–7.25 (m, 3H), 6.25 (s, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 151.7, 149.4, 144.9, 137.6, 134.9, 128.8, 128.5, 128.4, 125.6, 124.7, 52.7.

The title compounds were also obtained doing the reaction in toluene (4 mL); leading to the tetrazole **21a** (70.0 mg, 0.30 mmol, 59% yield) as an off-white solid, and tetrazole **21b** (38.0 mg, 0.16 mmol, 32% yield) as a pale-yellow oil.

The title compounds were also prepared according to the general procedure **B1** using 2-pyridine-carbonitrile (60.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step) leading to tetrazole **21a** (67.1 mg, 0.28 mmol, 49% yield) as an off-white solid and tetrazole **21b** (35.6 mg, 0.15 mmol, 26% yield) as a bright yellow oil.



22a



22b

Ethyl 2-(2-benzyl-2H-tetrazol-5-yl)acetate (22a) and Ethyl 2-(1-benzyl-1H-tetrazol-5-yl)acetate (22b).


The title compounds were prepared according to the general procedure **A** using ethyl 1H-tetrazole-5-acetate (78.1 mg, 0.500 mmol, 1.00 equiv), benzylamine (0.147 mL, 1.25 mmol, 2.50 equiv) and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in EtOAc (4 mL). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 40% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **22a** (76.0 mg, 0.31 mmol, 62% yield) was isolated as a clear oil. Spectral data matched those reported in the literature.¹⁵ R_f 0.47 (40% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38–7.33 (m, 5H), 5.75 (s, 2H), 4.19 (q, $J=7.1$ Hz, 2H), 3.95 (s, 2H), 1.24 (t, $J=7.1$ Hz, 3H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 168.4, 160.2, 133.3, 129.2, 129.1, 128.5, 61.7, 56.9, 32.0, 14.2.

Tetrazole **22b** (31.0 mg, 0.13 mmol, 25% yield) was isolated as a pale-yellow oil. Spectral data matched those reported in the literature.¹⁵ R_f 0.25 (40% EtOAc/hexanes). $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.39–7.35

¹⁴ C. Behloul, M. Benlahrech, F. Foubelo, C. Nájera, M. Yus, *Synthesis* **2018**, 50, 3430–3435.


¹⁵ H. Kanno, H. Yamaguchi, Y. Ichikawa, S. Isoda, *Chem. Pharm. Bull.* **1991**, 39, 1099–1105.

(m, 3H), 7.21-7.18 (m, 2H), 5.61 (s, 2H), 4.13 (q, $J=7$ Hz, 2H), 3.81 (s, 2H), 1.22 (t, $J=7$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 166.6, 149.2, 132.8, 129.4, 129.3, 127.9, 62.4, 51.7, 30.1, 14.1.



2-(4-Bromophenethyl)-5-(2,4-dimethoxyphenyl)-2H-tetrazole (25a) and 1-(4-bromophenethyl)-5-(2,4-dimethoxyphenyl)-1H-tetrazole (25b). The title compounds were prepared according to the general procedure **B2** using 3,5-dimethoxybenzonitrile (81.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 4-bromophenethylamine (250 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 25% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **25a** (101 mg, 0.26 mmol, 52% yield) was isolated as a sticky light-brown oil. R_f 0.20 (25% EtOAc/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.88 (d, $J = 8.4$ Hz, 1H), 7.40 (d, $J = 8.3$ Hz, 2H), 7.04 (d, $J = 8.3$ Hz, 2H), 6.62-6.56 (m, 2H), 4.84 (t, $J = 7.5$ Hz, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 3.31 (t, $J = 7.5$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.3, 162.2, 158.8, 135.7, 131.9, 131.7, 130.5, 121.1, 109.4, 105.1, 99.2, 56.1, 55.5, 53.8, 35.2; FTIR (cm^{-1}) (neat) 3200-2800, 1613, 1536, 1453, 1262, 1209, 1162, 766, 686; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{17}\text{H}_{17}\text{BrN}_4\text{O}_2\text{Na}$ 411.0427, found 411.0422.


Tetrazole **25b** (35.0 mg, 0.090 mmol, 18% yield) was isolated as a pale-yellow oil. R_f 0.28 (50% EtOAc/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.27 (d, $J = 8.3$ Hz, 2H), 7.00 (d, $J = 8.4$ Hz, 1H), 6.76 (d, $J = 8.3$ Hz, 2H), 6.54 (dd, $J = 8.4$ Hz, 2.2 Hz, 1H), 6.51 (d, $J = 2.1$ Hz, 1H), 4.44 (t, $J = 7.1$ Hz, 2H), 3.87 (s, 3H), 3.77 (s, 3H), 3.10 (t, $J = 7.1$ Hz, 2H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.6, 157.9, 153.0, 135.8, 132.8, 131.9, 130.4, 121.2, 105.4, 99.0, 55.9, 55.8, 49.0, 35.4; FTIR (cm^{-1}) (neat) 3200-2800, 1615, 1548, 1437, 1290, 1210, 1162, 771; HRMS (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{17}\text{H}_{17}\text{BrN}_4\text{O}_2\text{Na}$ 411.0427, found 411.0414.



5-(2-Bromophenyl)-2-cyclohexyl-2H-tetrazole (26a) and 5-(2-bromophenyl)-1-cyclohexyl-1H-tetrazole (26b). The title compounds were prepared according to the general procedure **B2** using 2-bromobenzonitrile (91.0 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), cyclohexylamine (124 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **26a** (49.2 mg, 0.16 mmol, 32% yield) was isolated as a pale-yellow oil. R_f 0.59 (20% EtOAc/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.86 (dd, $J = 7.7$ Hz, 1.6 Hz, 1H), 7.73 (dd, $J = 8.0$ Hz, 0.8 Hz, 1H), 7.42 (td, $J = 7.6$ Hz, 1.0 Hz, 1H), 7.32 (td, $J = 7.7$ Hz, 1.6 Hz, 1H), 4.79 (tt, $J = 11.2$ Hz, 3.9 Hz, 1H), 2.36-2.27 (m, 2H), 2.06 (td, $J = 12.1$ Hz, 3.4 Hz, 2H), 2.01-1.92 (m, 2H), 1.81-1.73 (m, 1H), 1.51 (qt, $J = 12.7$ Hz, 3.4 Hz, 2H), 1.36 (tt, $J = 12.2$ Hz, 3.4 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.7, 134.2, 131.8,


131.2, 129.1, 127.5, 122.3, 63.5, 32.6, 25.1, 24.9; **FTIR** (cm⁻¹) (neat) 3200-2800, 1600, 1519, 1452, 823, 746; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₃H₁₆BrN₄ 307.0553, found 307.0548.

Tetrazole **26b** (20.0 mg, 0.065 mmol, 13% yield) was isolated as a light-brown oil. **R_f** 0.23 (20% EtOAc/hexanes); **¹H NMR** (400 MHz, CDCl₃) δ 7.78-7.73 (m, 1H), 7.53-7.44 (m, 2H), 7.39-7.35 (m, 1H), 4.00 (quint, *J* = 7.8 Hz, 1H), 2.08-1.97 (m, 4H), 1.94-1.83 (m, 2H), 1.74-1.56 (m, 2H), 1.36-1.20 (m, 4H); **¹³C NMR** (100 MHz, CDCl₃) δ 153.0, 133.6, 132.7, 132.0, 128.0, 126.8, 123.6, 58.7, 32.9, 25.3, 24.9; **FTIR** (cm⁻¹) (neat) 3200-2800, 1451, 1532, 1600, 1401, 767, 707; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₃H₁₆BrN₄ 307.0553, found 307.0548.



2-Phenethyl-5-(2-nitrophenyl)-2H-tetrazole (27a) and 1-phenethyl-5-(2-nitrophenyl)-1H-tetrazole (27b). The title compounds were prepared according to the general procedure **B2** using 2-nitrobenzonitrile (74.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 35% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **27a** (100 mg, 0.34 mmol, 68% yield) was isolated as a clear oil. **R_f** 0.57 (35% EtOAc/hexanes); **¹H NMR** (400 MHz, CDCl₃) δ 7.92 (dd, *J* = 7.7 Hz, 1.4 Hz, 1H), 7.87 (dd, *J* = 8.0 Hz, 1.2 Hz, 1H), 7.69 (td, *J* = 7.6 Hz, 1.3 Hz, 1H), 7.62 (td, *J* = 7.8 Hz, 1.4 Hz, 1H), 7.33-7.28 (m, 2H), 7.24 (tt, *J* = 7.3 Hz, 2.6 Hz, 1H), 7.18-7.14 (m, 2H), 4.88 (t, *J* = 7.5 Hz, 2H), 3.35 (t, *J* = 7.5 Hz, 2H); **¹³C NMR** (100 MHz, CDCl₃) δ 161.4, 149.1, 136.3, 132.4, 131.2, 131.1, 128.9, 128.7, 127.3, 124.2, 121.6, 54.6, 35.7; **FTIR** (cm⁻¹) (neat) 3200-2800, 1529, 1454, 1355, 738, 699; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₄N₅O₂ 296.1142, found 296.1144.


Tetrazole **27b** (29.5 mg, 0.10 mmol, 20% yield) was isolated as a clear oil. **R_f** 0.27 (35% EtOAc/hexanes); **¹H NMR** (500 MHz, CDCl₃) δ 8.25 (dd, *J* = 8.3 Hz, 1.0 Hz, 1H), 7.74-7.69 (m, 1H), 7.56 (td, *J* = 7.6 Hz, 1.2 Hz, 1H), 7.27-7.22 (m, 1H), 7.21-7.16 (m, 2H), 6.88-6.85 (m, 2H), 6.52 (dd, *J* = 7.6 Hz, 1.3 Hz, 1H), 4.34 (t, *J* = 6.8 Hz, 2H), 3.24 (t, *J* = 6.78 Hz, 2H); **¹³C NMR** (125 MHz, CDCl₃) δ 152.5, 147.6, 136.5, 134.0, 132.8, 132.3, 129.1, 128.9, 127.4, 125.3, 119.8, 49.4, 35.8; **FTIR** (cm⁻¹) (neat) 3200-2800, 1529, 1455, 1346, 745, 700; **HRMS** (ESI-TOF) m/z: [M+H]⁺ Calcd for C₁₅H₁₄N₅O₂ 296.1142, found 296.1150.




3-(2-Allyl-2H-tetrazol-5-yl)pyridine (28a) and 3-(1-allyl-1H-tetrazol-5-yl)pyridine (28b). The title compounds were prepared according to the general procedure **B1** using 3-pyridinecarbonitrile (52.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), allylamine (71.4 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 50% then 300 mL 100% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **28a** (38.0 mg, 0.20 mmol, 41% yield) was isolated as a pale-yellow oil. **R_f** 0.39 (50% EtOAc/hexanes); **¹H NMR** (400 MHz,

CDCl₃) δ 9.37 (d, J = 1.4 Hz, 1H), 8.70 (dd, J = 4.8 Hz, 1.6 Hz, 1H), 8.41 (dt, J = 7.9 Hz, 1.9 Hz, 1H), 7.42 (ddd, J = 7.9 Hz, 4.9 Hz, 0.7 Hz, 1H), 6.13 (m, 1H), 5.45 (s, 1H), 5.41 (dd, J = 5.5 Hz, 0.5 Hz, 1H), 5.28 (dd, J = 6.3 Hz, 1.3 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 163.1, 151.4, 148.3, 134.2, 129.7, 123.8, 123.7, 121.4, 55.7; FTIR (cm⁻¹) (neat) 3200-2800, 1689, 1647, 1603, 1519, 1432, 791, 707; HRMS (ESI-TOF) m/z : [M+H]⁺ Calcd for C₉H₁₀N₅ 188.0930, found 188.0923.

Tetrazole **28b** (11.0 mg, 0.059 mmol, 12% yield) was isolated as a yellow oil; R_f 0.30 (100% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 8.96 (d, J = 1.8 Hz, 1H), 8.83 (dd, J = 4.8 Hz, 1.4 Hz, 1H), 8.10 (dt, J = 8.0 Hz, 1.9 Hz, 1H), 7.52 (dd, J = 7.9 Hz, 4.9 Hz, 1H), 6.12-6.00 (m, 1H), 5.41 (d, J = 10.4 Hz, 1H), 5.17-5.07 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 152.5, 152.3, 149.1, 136.5, 130.4, 124.1, 120.6, 120.3, 50.4; FTIR (cm⁻¹) (neat) 3200-2800, 1688, 1647, 1602, 1529, 1446, 816, 708; HRMS (ESI-TOF) m/z : [M+H]⁺ Calcd for C₉H₁₀N₅ 188.0930, found 188.0922.




29a




29b

3-(2-(2-Bromo-4,5-dimethoxyphenethyl)-2H-tetrazol-5-yl)-2-fluoropyridine (29a) and 3-(1-(2-bromo-4,5-dimethoxyphenethyl)-1H-tetrazol-5-yl)-2-fluoropyridine (29b). The title compounds were prepared according to the general procedure **B1** using 3-cyano-2-fluoropyridine (61.0 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 2-bromo-4,5-dimethoxyphenethylamine (325 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 30% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **29a** (148 mg, 0.36 mmol, 60% yield) was isolated as an off-white solid. R_f 0.60 (50% EtOAc/hexanes); mp 130-134 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (ddd, J = 2.0 Hz, 7.6 Hz, 9.3 Hz, 1H), 8.34 (qd, J = 1.0 Hz, 4.8 Hz, 1H), 7.36 (ddd, J = 1.7 Hz, 4.9 Hz, 6.2 Hz, 1H), 7.01 (s, 1H), 6.56 (s, 1H), 4.95 (t, J = 7.3 Hz, 2H), 3.84 (s, 3H), 3.72 (s, 3H), 3.45 (t, J = 7.2 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 160.2 (d, J = 246.0 Hz), 160.0 (d, J = 9.3 Hz), 149.4 (d, J = 14.7 Hz), 148.8 (d, J = 48.1 Hz), 140.5 (d, J = 2.9 Hz), 127.5, 121.9 (d, J = 4.6 Hz), 115.8, 114.3, 113.4, 111.2, 111.0, 56.3, 56.1, 53.0, 35.8; ¹⁹F NMR (375 MHz, CDCl₃) δ -64.88 (d, J = 9.1 Hz); FTIR (cm⁻¹) (neat) 3200-2800, 1604, 1508, 1446, 1259, 1214, 1101, 730, 700; HRMS (ESI-TOF) m/z : [M+Na]⁺ Calcd for C₁₆H₁₅BrN₅O₂Na 430.0285, found 430.0284.

Tetrazole **29b** (69.3 mg, 0.17 mmol, 28% yield) was isolated as a red-brownish sticky oil; R_f 0.29 (50% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, J = 4.8 Hz, 1H), 7.54 (ddd, J = 9.2 Hz, 7.6 Hz, 1.9 Hz, 1H), 7.22 (ddd, J = 7.1 Hz, 5.0 Hz, 2.0 Hz, 1H), 6.68 (s, 1H), 6.10 (s, 1H), 4.74 (t, J = 6.5 Hz, 2H), 3.79 (s, 3H), 3.67 (s, 3H), 3.19 (t, J = 6.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 159.1 (d, J = 240.1 Hz), 150.8 (d, J = 15.1 Hz), 150.1 (d, J = 5.4 Hz), 148.9 (d, J = 33.3 Hz), 142.5 (d, J = 2.8 Hz), 127.0, 121.7 (d, J = 4.5 Hz), 115.6, 114.1, 113.0, 107.7, 107.4, 56.3, 56.2, 47.9 (d, J = 6.1 Hz), 36.5; ¹⁹F NMR (375 MHz, CDCl₃) δ -65.44 (d, J = 9.0 Hz); FTIR (cm⁻¹) (neat) 3200-2800, 1603, 1509, 1457, 1259, 1222, 1099, 732; HRMS (ESI-TOF) m/z : [M+H]⁺ Calcd for C₁₆H₁₆BrN₅O₂ 408.0466, found 408.0468.




30a




30b

1-(2-(3-Isopropoxypropyl)-2H-tetrazol-5-yl)isoquinoline (30a) and 1-(1-(3-isopropoxypropyl)-1H-tetrazol-5-yl)isoquinoline (30b). The title compounds were prepared according to the general procedure **B1** using 1-isoquinolinecarbonitrile (77.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 3-isopropoxypropylamine (146 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 25% then 300 mL 40% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **30a** (46.1 mg, 0.16 mmol, 31% yield) was isolated as a pale-yellow oil. R_f 0.28 (50% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.17 (d, J = 8.4 Hz, 1H), 8.74 (d, J = 5.6 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 7.81-7.68 (m, 3H), 4.92 (t, J = 6.9 Hz, 2H), 3.57 (hept, J = 6.1 Hz, 1H), 3.51 (t, J = 5.8 Hz, 2H), 2.40 (quint, J = 6.4 Hz, 2H), 1.15 (d, J = 6.1 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.1, 146.6, 142.6, 137.1, 130.6, 128.6, 127.3, 127.2, 127.0, 122.7, 72.0, 64.2, 51.1, 30.1, 22.2; **FTIR** (cm^{-1}) (neat) 3200-2800, 1622, 1497, 1446, 1126, 1087, 799, 709; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{N}_5\text{O}$ 320.1482, found 320.1483.

Tetrazole **30b** (78.8 mg, 0.27 mmol, 53% yield) was isolated as a pale-yellow oil; R_f 0.28 (50% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.85 (d, J = 8.5, 1H), 8.68 (d, J = 5.6 Hz, 1H), 7.94 (d, J = 8.2 Hz, 1H), 7.84 (d, J = 5.6 Hz, 1H), 7.79 (td, J = 7.5 Hz, 0.8 Hz, 1H), 7.75-7.69 (m, 1H), 4.91 (t, J = 6.9 Hz, 2H), 3.40-3.32 (m, 3H), 2.17 (quint, J = 6.4 Hz, 2H), 0.97 (d, J = 6.1 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 152.0, 144.7, 141.9, 137.0, 131.2, 129.1, 127.8, 127.2, 127.1, 123.3, 71.7, 64.3, 46.8, 30.5, 22.0; **FTIR** (cm^{-1}) (neat) 3200-2800, 1718, 1622, 1493, 1452, 1128, 1085, 801, 686; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{19}\text{N}_5\text{O}$ 320.1482, found 320.1476.



32a




32b

2-(5-Benzyl-2H-tetrazol-2-yl)-N,N-diethylethan-1-amine (32a) 2-(5-benzyl-1H-tetrazol-1-yl)-N,N-diethylethan-1-amine (32b). The title compounds were prepared according to the general procedure **B2** using benzyl cyanide (58.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 2-diethylaminoethylamine (145 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 75% then 300 mL 100% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **32a** (83.0 mg, 0.32 mmol, 64% yield) was isolated as a clear oil as previously reported.⁷ R_f 0.37 (75% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.32-7.25 (m, 4H), 7.24-7.18 (m, 1H), 4.59 (t, J = 6.9 Hz, 2H), 4.23 (s, 2H), 3.01 (t, J = 6.7 Hz, 2H), 2.52 (q, J = 7.1 Hz, 4H), 0.95 (t, J = 7.1 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 165.4, 136.9, 128.8, 128.7, 126.9, 51.8, 51.5, 47.4, 31.9, 12.1; **FTIR** (cm^{-1}) (neat) 3200-2800, 1604, 1495, 1454, 1137, 1073, 1028, 735, 697; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{26}\text{N}_5$ 260.1870, found 260.1857.

Tetrazole **32b** (25.9 mg, 0.10 mmol, 20% yield) was isolated as a clear oil; R_f 0.20 (100% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.34-7.25 (m, 3H), 7.17 (d, J = 7.1 Hz, 2H), 4.36 (s, 2H), 4.13 (t, J = 6.3 Hz, 2H), 2.72 (t, J = 6.3 Hz, 2H), 2.43 (q, J = 7.1 Hz, 4H), 0.87 (t, J = 7.2 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.3, 134.4, 129.2, 128.5, 127.7, 52.7, 47.6, 46.6, 29.6, 11.9; **FTIR** (cm^{-1}) (neat) 3200-2800, 1604, 196,

1456, 1105, 1073, 1031, 732, 697; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{14}H_{26}N_5$ 260.1870, found 260.1866.




33a

33b

2-Benzyl-5-methyl-2H-tetrazole (33a) and 1-benzyl-5-methyl-1H-tetrazole (33b). The title compounds were prepared according to the general procedure **B2** using acetonitrile (0.261 mL, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 25% then 300 mL 60% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **33a** (47.0 mg, 0.27 mmol, 54% yield) was isolated as a clear oil as previously reported.⁷ R_f 0.39 (25% EtOAc/hexanes); 1H NMR (400 MHz, $CDCl_3$) δ 7.36 (s, 5H), 5.69 (s, 2H), 2.51 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.4, 133.5, 129.1, 129.0, 128.5, 56.6, 11.0; **FTIR** (cm^{-1}) (neat) 3200-2800, 1606, 1498, 1456, 802, 733; **HRMS** (ESI-TOF) m/z : $[M+Na]^+$ Calcd for $C_9H_{10}N_4Na$ 197.0798, found 197.0793.

Tetrazole **33b** (13.9 mg, 0.080 mmol, 16% yield) was isolated as a pale-yellow oil. Spectral data matched those reported in the literature.¹² R_f 0.50 (75% EtOAc/hexanes); 1H NMR (400 MHz, $CDCl_3$) δ 7.39-7.34 (m, 3H), 7.22-7.17 (m, 2H), 5.50 (s, 2H), 2.44 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 151.8, 133.2, 129.4, 129.1, 127.6, 51.0, 9.1.





34a

34b



4-((5-Cyclopropyl-2H-tetrazol-2-yl)methyl)pyridine (34a) and 4-((5-cyclopropyl-1H-tetrazol-1-yl)methyl)pyridine (34b). The title compounds were prepared according to the general procedure **B2** using cyclopropanecarbonitrile (33.5 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 3-picolylamine (135 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL EtOAc then 300 mL 5% MeOH/EtOAc) to separate the two tetrazole isomers. Tetrazole **34a** (50.3 mg, 0.25 mmol, 50% yield) was isolated as a clear oil. R_f 0.35 (100% EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 8.62 (d, J = 5.9 Hz, 2H), 7.18 (d, J = 5.6 Hz, 2H), 5.69 (s, 2H), 2.22-2.14 (m, 1H), 1.12-1.05 (m, 4H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 169.7, 150.6, 142.2, 122.6, 55.1, 8.6, 6.7; **FTIR** (cm^{-1}) (neat) 3200-2800, 1603, 1516, 1417, 771, 688; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{10}H_{12}N_5$ 202.1087, found 202.1088.

Tetrazole **34b** (26.2 mg, 0.13 mmol, 26% yield) was isolated as a clear oil. R_f 0.14 (100% EtOAc); 1H NMR (400 MHz, $CDCl_3$) δ 8.64 (d, J = 5.9 Hz, 2H), 7.08 (d, J = 5.6 Hz, 2H), 5.60 (s, 2H), 1.75-1.66 (m, 1H), 1.24-1.18 (m, 2H), 1.17-1.10 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 157.5, 150.9, 142.5, 121.8, 49.3, 9.2, 4.1; **FTIR** (cm^{-1}) (neat) 3200-2800, 1603, 1542, 1416, 769, 722; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{10}H_{12}N_5$ 202.1087, found 202.1087.



2-Phenethyl-5-(3,5-dimethylphenyl)-2H-tetrazole (35a) and 1-phenethyl-5-(3,5-dimethylphenyl)-1H-tetrazole (35b). The title compounds were prepared according to the general procedure **B2** using 3,5-dimethylbenzonitrile (65.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **35a** (82.1 mg, 0.29 mmol, 59% yield) was isolated as a white solid. R_f 0.63 (25% EtOAc/hexanes); mp 95–98 °C; 1H NMR (500 MHz, $CDCl_3$) δ 7.78 (s, 2H), 7.33–7.29 (m, 2H), 7.28–7.23 (m, 1H), 7.22–7.18 (m, 2H), 7.13–7.10 (m, 1H), 4.87 (t, J = 7.7 Hz, 2H), 3.38 (t, J = 7.7 Hz, 2H), 2.40 (s, 6H); ^{13}C NMR (125 MHz, $CDCl_3$) 165.5, 138.7, 136.6, 132.1, 129.0, 128.8, 127.3, 127.28, 124.7, 54.3, 35.9, 21.4; FTIR (cm^{-1}) (neat) 3200–2800, 1607, 1498, 1362, 1031, 855, 736, 691; HRMS (ESI-TOF) m/z : $[M+H]^+$ calcd for $C_{17}H_{19}N_4$ 279.1604, found 279.1608.



Tetrazole **35b** (30.6 mg, 0.11 mmol, 22% yield) was isolated as a clear oil. R_f 0.25 (25% EtOAc/hexanes); 1H NMR (400 MHz, $CDCl_3$) δ 7.25–7.21 (m, 3H), 7.12 (s, 2H), 6.97–6.92 (m, 2H), 6.80 (s, 2H), 4.57 (t, J = 7.0 Hz, 2H), 3.26 (t, J = 7.0 Hz, 2H), 2.31 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 155.2, 138.9, 136.5, 129.0, 128.9, 127.3, 126.5, 123.6, 49.2, 36.2, 21.3; FTIR (cm^{-1}) (neat) 3200–2800, 1605, 1455, 1397, 858, 752, 699; HRMS (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{17}H_{19}N_4$ 279.1604, found 279.1609.



2-Phenethyl-5-phenyl-2H-tetrazole (36a) and 1-phenethyl-5-phenyl-1H-tetrazole (36b). The title compounds were prepared according to the general procedure **B2** using benzonitrile (0.47 mL, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **36a** (87.6 mg, 0.35 mmol, 70% yield) was isolated as a clear oil. R_f 0.63 (25% EtOAc/hexanes); 1H NMR (400 MHz, $CDCl_3$) δ 8.24–8.14 (m, 2H), 7.57–7.48 (m, 3H), 7.38–7.21 (m, 5H), 4.91 (t, J = 7.7 Hz, 2H), 3.42 (t, J = 7.7 Hz, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) 165.2, 136.6, 130.4, 129.0, 128.9, 127.5, 127.3, 126.9, 54.3, 35.8; FTIR (cm^{-1}) (neat) 3200–2800, 1997, 1450, 732, 694; HRMS (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{15}H_{15}N_4$ 251.1291, found 251.1294.



Tetrazole **36b** (21.3 mg, 0.085 mmol, 17% yield) was isolated as a clear oil. Spectral data matched those reported in the literature.¹⁶ R_f 0.25 (25% EtOAc/hexanes); 1H NMR (500 MHz, $CDCl_3$) δ 7.50 (tt, J = 7.5 Hz, 1.3 Hz, 1H), 7.45–7.41 (m, 2H), 7.28–7.24 (m, 2H), 7.21–7.17 (m, 3H), 6.95–6.90 (m, 2H), 4.60 (t, J = 7.1 Hz, 2H), 3.23 (t, J = 7.1 Hz, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 154.8, 136.2, 131.1, 129.1, 128.9, 128.73, 128.70, 127.4, 123.8, 49.2, 36.1.

¹⁶ A. L. Chandgude, A. Dömling, *Eur. J. Org. Chem.* **2016**, 2383–2387.



2-Phenethyl-5-(3-bromophenyl)-2H-tetrazole (37a) and 1-phenethyl-5-(3-bromophenyl)-1H-tetrazole (37b). The title compounds were prepared according to the general procedure **B2** using 3-bromobenzonitrile (91.0 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **37a** (127 mg, 0.39 mmol, 77% yield) was isolated as a white solid as previously reported.⁷ *R_f* 0.64 (25% EtOAc/hexanes); *mp* 82–86 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1H), 8.08 (d, *J* = 7.7 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.40–7.25 (m, 4H), 7.20 (d, *J* = 7.3 Hz, 2H), 4.88 (t, *J* = 7.7 Hz, 2H), 3.38 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) 163.9, 136.4, 133.4, 130.6, 129.9, 129.5, 129.0, 128.8, 127.4, 125.5, 123.1, 54.5, 35.8; FTIR (cm⁻¹) (neat) 3200–2800, 1604, 1517, 1439, 749, 681, 652; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₁₅H₁₄BrN₄ 329.0396, found 329.0397.


Tetrazole **37b** (29.6 mg, 0.090 mmol, 18% yield) was isolated as a clear oil. *R_f* 0.26 (25% EtOAc/hexanes); ¹H NMR (500 MHz, CDCl₃) δ 7.65–7.61 (m, 1H), 7.30 (t, *J* = 7.9 Hz, 1H), 7.27–7.19 (m, 4H), 7.17–7.14 (m, 1H), 6.90–6.87 (m, 2H), 4.60 (t, *J* = 6.8 Hz, 2H), 3.25 (t, *J* = 6.8 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.9, 136.1, 134.2, 131.8, 130.6, 129.2, 128.8, 127.6, 127.3, 125.8, 123.2, 49.5, 36.3; FTIR (cm⁻¹) (neat) 3200–2800, 1603, 1496, 1455, 740, 700, 669; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₁₄BrN₄ 329.0396, found 329.0404.



2-Phenethyl-5-(3-nitrophenyl)-2H-tetrazole (38a) and 1-phenethyl-5-(3-nitrophenyl)-1H-tetrazole (38b). The title compounds were prepared according to the general procedure **B2** using 3-nitrobenzonitrile (74.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **38a** (108 mg, 0.37 mmol, 73% yield) was isolated as a white solid. *R_f* 0.54 (25% EtOAc/hexanes); *mp* 79–83 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.99 (t, *J* = 1.8 Hz, 1H), 8.48 (dt, *J* = 7.8 Hz, 1.2 Hz, 1H), 8.32 (ddd, *J* = 8.1 Hz, 2.1 Hz, 1.0 Hz, 1H), 7.69 (t, *J* = 8.0 Hz, 1H), 7.35–7.29 (m, 2H), 7.28–7.23 (m, 1H), 7.23–7.18 (m, 2H), 4.92 (t, *J* = 7.6 Hz, 2H), 3.40 (t, *J* = 7.6 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) 163.4, 148.8, 136.3, 132.6, 130.2, 129.3, 129.0, 128.8, 127.5, 125.0, 122.0, 54.6, 35.8; FTIR (cm⁻¹) (neat) 3200–2800, 1541, 1512, 1344, 748, 723; HRMS (ESI-TOF) *m/z*: [M+H]⁺ calcd for C₁₅H₁₄N₅O₂ 296.1142, found 296.1146.


Tetrazole **38b** (17.7 mg, 0.057 mmol, 12% yield) was isolated as a yellow sticky oil. *R_f* 0.15 (25% EtOAc/hexanes); ¹H NMR (500 MHz, CDCl₃) δ 8.34 (ddd, *J* = 8.3 Hz, 2.2 Hz, 1.1 Hz, 1H), 8.02 (t, *J* = 1.9 Hz, 1H), 7.61 (t, *J* = 8.0 Hz, 1H), 7.53 (ddd, *J* = 7.7 Hz, 1.6 Hz, 1.1 Hz, 1H), 7.19–7.13 (m, 3H), 6.87–6.82 (m, 2H), 4.67 (t, *J* = 6.6 Hz, 2H), 3.27 (t, *J* = 6.6 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.2, 148.4, 135.8, 134.7, 130.4, 129.2, 128.8, 127.7, 125.7, 125.6, 123.7, 49.8, 36.4; FTIR (cm⁻¹) (neat) 3200–2800, 1717,

1641, 1515, 1496, 1364, 698; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ calcd for $C_{15}H_{14}N_5O_2$ 296.1142, found 296.1143.




2-Phenethyl-5-(4-nitrophenyl)-2H-tetrazole (39a) and 1-phenethyl-5-(4-nitrophenyl)-1H-tetrazole (39b). The title compounds were prepared according to the general procedure **B2** using 4-nitrobenzonitrile (74.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **39a** (118 mg, 0.40 mmol, 80% yield) was isolated as a white crystalline solid as previously reported.⁷ R_f 0.55 (25% EtOAc/hexanes); **mp** 143-146 °C; 1H NMR (500 MHz, $CDCl_3$) δ 8.37-8.30 (m, 4H), 7.34-7.29 (m, 2H), 7.26 (tt, J = 7.3 Hz, 1.3 Hz, 1H), 7.22-7.18 (m, 2H), 4.92 (t, J = 7.7 Hz, 2H), 3.40 (t, J = 7.6 Hz, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) 163.3, 149.0, 136.2, 133.4, 129.0, 128.7, 127.7, 127.4, 124.3, 54.6, 35.8; **FTIR** (cm^{-1}) (neat) 3200-2800, 1604, 1515, 1454, 1334, 1046; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ calcd for $C_{15}H_{14}N_5O_2$ 296.1142, found 296.1152.


Tetrazole **39b** (11.7 mg, 0.40 mmol, 8% yield) was isolated as a white crystalline solid. R_f 0.21 (25% EtOAc/hexanes); **mp** 124-127 °C; 1H NMR (500 MHz, $CDCl_3$) δ 8.24 (dt, J = 8.9 Hz, 2.2 Hz, 2H), 7.30 (dt, J = 8.9 Hz, 2.2 Hz, 2H), 7.24-7.17 (m, 3H), 6.87-6.83 (m, 2H), 4.63 (t, J = 6.6 Hz, 2H), 3.28 (t, J = 6.6 Hz, 2H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 153.5, 149.3, 136.0, 130.1, 130.0, 129.2, 128.8, 127.8, 124.2, 49.8, 36.4; **FTIR** (cm^{-1}) (neat) 3200-2800, 1611, 1523, 1452, 1340, 1105, 853, 689; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{15}H_{14}N_5O_2$ 296.1142, found 296.1143.



2-Phenethyl-5-(3,5-dinitrophenyl)-2H-tetrazole (40). The title compound was prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), phenethylamine (0.157 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **40** (148 mg, 0.43 mmol, 87% yield) was isolated as an orange crystalline solid. R_f 0.50 (25% EtOAc/hexanes); **mp** 120-124 °C; 1H NMR (400 MHz, $CDCl_3$) δ 9.30 (d, J = 2.0 Hz, 2H), 9.13 (t, J = 2.0 Hz, 1H), 7.35-7.25 (m, 3H), 7.23-7.18 (m, 2H), 4.97 (t, J = 7.6 Hz, 2H), 3.43 (t, J = 7.6 Hz, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) 161.7, 149.2, 136.0, 131.2, 129.1, 128.7, 127.6, 126.8, 119.9, 54.9, 35.8; **FTIR** (cm^{-1}) (neat) 3200-2800, 1598, 1543, 1519, 1496, 1455, 1383, 1342, 730, 704, 654; **HRMS** (ESI-TOF) m/z : $[M+H]^+$ Calcd for $C_{15}H_{14}N_6O_4$ 341.0993 found 341.1000.




41a




41b

2-Benzyl-5-(3,5-dimethylphenyl)-2H-tetrazole (41a) and 1-benzyl-5-(3,5-dimethyl phenyl)-1H-tetrazole (41b). The title compounds were prepared according to the general procedure **B2** using 3,5-dimethylbenzonitrile (65.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **41a** (72.7 mg, 0.28 mmol, 55% yield) was isolated as a white solid. R_f 0.71 (25% EtOAc/hexanes); mp 52-57 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.79-7.76 (m, 2H), 7.43-7.35 (m, 5H), 7.10-7.08 (m, 1H), 5.80 (s, 2H), 2.38 (d, J = 0.5 Hz, 6H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) 165.8, 138.6, 133.5, 132.1, 129.1, 129.0, 128.4, 127.2, 124.7, 56.8, 21.3; **FTIR** (cm^{-1}) (neat) 3200-2800, 1609, 1522, 1501, 1460, 1108, 872, 731, 698; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{17}\text{N}_4$ 265.1448 found 265.1451.

Tetrazole **41b** (31.7 mg, 0.12 mmol, 24% yield) was isolated as a clear oil. R_f 0.47 (25% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.37-7.32 (m, 3H), 7.21-7.14 (m, 5H), 5.59 (s, 2H), 2.33 (s, 6H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 155.1, 139.1, 134.3, 133.0, 129.2, 128.9, 127.5, 126.7, 123.6, 51.5, 21.3; **FTIR** (cm^{-1}) (neat) 3200-2800, 1606, 1524, 1498, 1456, 1111, 858, 725, 696; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{17}\text{N}_4$ 265.1448 found 265.1450.




42a



42b


2-Benzyl-5-(3-bromophenyl)-2H-tetrazole (42a) and 1-benzyl-5-(3-bromophenyl)-1H-tetrazole (42b). The title compounds were prepared according to the general procedure **B2** using 3-bromobenzonitrile (91.0 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 10% then 300 mL 25% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **42a** (102.5 mg, 0.33 mmol, 65% yield) was isolated as a white solid. Spectral data matched those reported in the literature.⁹ R_f 0.60 (25% EtOAc/hexanes); mp 94-96 °C; $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 8.30 (t, J = 1.7 Hz, 1H), 8.09-8.05 (m, 1H), 7.58 (dq, J = 8.0 Hz, 1.0 Hz, 1H), 7.44-7.31 (m, 6H), 5.80 (s, 2H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) 164.3, 133.4, 133.3, 130.5, 129.9, 129.4, 129.19, 129.18, 128.5, 125.5, 123.0, 57.1.

Tetrazole **42b** (42.3 mg, 0.13 mmol, 26% yield) was isolated as a clear oil. R_f 0.31 (25% EtOAc/hexanes); $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.72 (t, J = 1.7 Hz, 1H), 7.71-7.66 (m, 1H), 7.51 (dt, J = 7.8 Hz, 1.2 Hz, 1H), 7.40-7.34 (m, 4H), 7.20-7.14 (m, 2H), 5.62 (s, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 153.5, 134.5, 133.7, 132.0, 130.8, 129.4, 129.1, 127.5, 127.4, 125.8, 123.3, 51.7; **FTIR** (cm^{-1}) (neat) 3200-2800, 1558, 1526, 1453, 1344, 722, 700, 658; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ Calcd for $\text{C}_{14}\text{H}_{12}\text{BrN}_4$ 315.0245, found 315.0247.



2-Benzyl-5-(3-nitrophenyl)-2H-tetrazole (43a) and 1-benzyl-5-(3-nitrophenyl)-1H-tetrazole (43b). The title compounds were prepared according to the general procedure **B2** using 3-nitrobenzonitrile (74.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 40% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **43a** (92.8 mg, 0.33 mmol, 66% yield) was isolated as a white crystalline solid. Spectral data matched those reported in the literature.¹⁷ *R_f* 0.53 (25% EtOAc/hexanes); *mp* 98-100 °C (litt. 82-84 °C);²¹ ¹H NMR (500 MHz, CDCl₃) δ 8.97 (t, *J* = 1.8 Hz, 1H), 8.47 (ddd, *J* = 7.8 Hz, 1.5 Hz, 1.1 Hz, 1H), 8.30 (ddd, *J* = 8.2 Hz, 2.3 Hz, 1.0 Hz, 1H), 7.66 (td, *J* = 8.0 Hz, 0.3 Hz, 1H), 7.46-7.43 (m, 2H), 7.42-7.35 (m, 3H), 5.83 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) 163.7, 148.7, 133.0, 132.6, 130.1, 129.3, 129.2, 128.6, 124.9, 122.0, 57.2.

Tetrazole **43b** (33.8 mg, 0.12 mmol, 24% yield) was isolated as a white solid. *R_f* 0.17 (25% EtOAc/hexanes); *mp* 115-119 °C; ¹H NMR (500 MHz, CDCl₃) δ 8.43 (t, *J* = 1.8 Hz, 1H), 8.40 (ddd, *J* = 8.3 Hz, 2.2 Hz, 1.0 Hz, 1H), 8.01 (ddd, *J* = 7.8 Hz, 1.6 Hz, 1.1 Hz, 1H), 7.72 (t, *J* = 7.9 Hz, 1H), 7.41-7.35 (m, 3H), 7.22-7.18 (m, 2H), 5.70 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 152.8, 148.5, 134.9, 133.2, 130.7, 129.6, 129.3, 127.3, 126.1, 125.6, 123.8, 52.1; FTIR (cm⁻¹) (neat) 3200-2800, 1520, 1456, 1349, 719, 672; HRMS (ESI-TOF) *m/z*: [M+H]⁺ Calcd for C₁₄H₁₂N₅O₂ 282.0986 found 282.0985.




2-Benzyl-5-(4-nitrophenyl)-2H-tetrazole (44a) and 1-benzyl-5-(4-nitrophenyl)-1H-tetrazole (44b). The title compounds were prepared according to the general procedure **B2** using 4-nitrobenzonitrile (74.1 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 35% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **44a** (94.2 mg, 0.34 mmol, 67% yield) was isolated as a white crystalline solid. Spectral data matched those reported in the literature.⁸ *R_f* 0.59 (25% EtOAc/hexanes); *mp* 138-143 °C (litt. 140-141 °C); ¹H NMR (500 MHz, CDCl₃) δ 8.31 (s, 4H), 7.46-7.37 (m, 5H), 5.84 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) 163.7, 149.0, 133.3, 133.0, 129.3, 129.2, 128.6, 127.8, 124.3, 57.3.

Tetrazole **44b** (25.3 mg, 0.90 mmol, 18% yield) was isolated as a white crystalline solid. Spectral data matched those reported in the literature.¹⁸ *R_f* 0.29 (35% EtOAc/hexanes); *mp* 124-127 °C (litt. 131-133 °C);²² ¹H NMR (500 MHz, CDCl₃) δ 8.35 (dt, *J* = 8.9 Hz, 2.2 Hz, 2H), 7.79 (dt, *J* = 8.9 Hz, 2.2 Hz, 2H), 7.40-7.35 (m, 3H), 7.16-7.11 (m, 2H), 5.68 (s, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 153.1, 149.6, 133.4, 130.2, 130.0, 129.6, 129.3, 127.1, 124.4, 52.0.


¹⁷ L. Wang, K. Zhu, Q. Chen, M. He, *J. Org. Chem.* **2014**, 79, 11780-11786.

¹⁸ A. R. Katritzky, C. Cai, N. K. Meher, *Synthesis* **2007**, 1204-1208.



2-Benzyl-5-(3,5-dinitrophenyl)-2H-tetrazole (45a) and 1-benzyl-5-(3,5-dinitrophenyl)-1H-tetrazole (45b). The title compounds were prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), benzylamine (0.137 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 40% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **45a** (114 mg, 0.35 mmol, 70% yield) was isolated as a white solid. Spectral data matched those reported in the literature.¹⁹ *R_f* 0.35 (25% EtOAc/hexanes); *mp* 107-111 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.29 (d, *J* = 2.0 Hz, 2H), 9.10 (t, *J* = 1.9 Hz, 1H), 7.49-7.38 (m, 5H), 5.87 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 162.1, 149.2, 132.6, 131.2, 129.5, 129.4, 128.8, 126.8, 119.9, 57.6.


Tetrazole **45b** (36.2 mg, 0.11 mmol, 22% yield) was isolated as a clear oil. Spectral data matched those reported in the literature.¹⁹ *R_f* 0.17 (25% EtOAc/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 9.16 (t, *J* = 1.9 Hz, 1H), 8.83 (d, *J* = 1.9 Hz, 2H), 7.45-7.38 (m, 3H), 7.27-7.21 (m, 2H), 5.80 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 151.1, 149.0, 132.5, 129.9, 129.8, 128.8, 127.5, 127.3, 121.0, 52.7.



5-(3,5-Dinitrophenyl)-2-(1-phenylethyl)-2H-tetrazole (46a) and 5-(3,5-dinitrophenyl)-1-(1-phenylethyl)-1H-tetrazole (46b). The title compounds were prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), (R)-(+)-phenylethylamine (0.159 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 30% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **46a** (85.1 mg, 0.25 mmol, 50% yield) was isolated as a clear sticky oil. *R_f* 0.57 (25% EtOAc/hexanes); ¹H NMR (500 MHz, CDCl₃) δ 9.31 (d, *J* = 2.1 Hz, 2H), 9.11 (t, *J* = 2.1 Hz, 1H), 6.19 (q, *J* = 7.1 Hz, 1H), 2.16 (d, *J* = 7.1 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 161.7, 149.2, 138.2, 131.4, 129.3, 126.9, 126.8, 119.9, 64.6, 21.1; FTIR (cm⁻¹) (neat) 3200-2800, 1556, 1519, 1345, 1077, 760, 725, 698; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd for C₁₅H₁₂N₆O₄Na 363.0812, found 363.0809.


Tetrazole **46b** (32.3 mg, 0.085 mmol, 19% yield) was isolated as a white solid. *R_f* 0.37 (25% EtOAc/hexanes); *mp* 163-165 °C; ¹H NMR (500 MHz, CDCl₃) δ 9.16 (t, *J* = 2.1 Hz, 1H), 8.71 (d, *J* = 2.1 Hz, 2H), 7.43 (tt, *J* = 7.2 Hz, 1.6 Hz, 2H), 7.38 (tt, *J* = 7.3 Hz, 1.4 Hz, 1H), 7.27-7.26 (m, 1H), 7.25-7.24 (m, 1H), 5.72 (q, *J* = 6.9 Hz, 1H), 2.13 (d, *J* = 7.0 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 151.0, 148.9, 138.9, 130.0, 129.6, 129.2, 128.0, 126.1, 120.9, 60.6, 23.4; FTIR (cm⁻¹) (neat) 3200-2800, 1594, 1557, 1525, 1346, 1081, 756, 725, 702; HRMS (ESI-TOF) *m/z*: [M+Na]⁺ calcd for C₁₅H₁₂N₆O₄Na 363.0812, found 363.0812

¹⁹ J. Němeček, P. Sychra, M. Macháček, M. Benková, G. Karabanovich, K. Konečná, V. Kavková, J. Stolaříková, A. Hrabálek, K. Vávrová, O. Soukup, J. Roh, V. Klimešová, *Eur. J. Med. Chem.* **2017**, *130*, 419-432.



5-(3,5-Dinitrophenyl)-2-(4-methoxybenzyl)-2H-tetrazole (47a) and 5-(3,5-dinitrophenyl)-1-(4-methoxybenzyl)-1H-tetrazole (47b). The title compounds were prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 4-methoxybenzylamine (0.163 mL, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 30% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **47a** (114 mg, 0.32 mmol, 64% yield) was isolated as a yellow sticky oil. R_f 0.41 (25% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 9.27 (d, J = 2.1 Hz, 2H), 9.09 (t, J = 2.1 Hz, 1H), 7.42 (dt, J = 8.8 Hz, 2.5 Hz, 2H), 6.92 (dt, J = 8.8 Hz, 2.5 Hz, 2H), 5.80 (s, 2H), 3.80 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) 162.0, 160.5, 149.1, 131.2, 130.4, 126.7, 124.7, 119.8, 114.6, 57.2, 55.5; **FTIR** (cm^{-1}) (neat) 3200-2800, 1556, 1516, 1345, 1251, 1179, 782, 726; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{12}\text{N}_6\text{O}_5\text{Na}$ 379.0761, found 379.0764.


Tetrazole **47b** (42.8 mg, 0.12 mmol, 24% yield) was isolated as a white solid; R_f 0.25 (25% EtOAc/hexanes); mp 160-164 $^\circ\text{C}$; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.17 (t, J = 1.8 Hz, 1H), 8.84 (d, J = 7.8 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.91 (d, J = 8.6 Hz, 2H), 5.73 (s, 2H), 3.80 (s, 3H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) δ 160.6, 151.0, 149.0, 129.0, 128.9, 127.6, 124.3, 121.0, 115.2, 55.6, 52.4; **FTIR** (cm^{-1}) (neat) 3200-2800, 1541, 1508, 1341, 1232, 1174, 779, 724; **HRMS** (ESI-TOF) m/z : $[\text{M}+\text{Na}]^+$ calcd for $\text{C}_{15}\text{H}_{12}\text{N}_6\text{O}_5\text{Na}$ 379.0761, found 379.0754.



5-(3,5-Dinitrophenyl)-2-(4-nitrobenzyl)-2H-tetrazole (48a) and 5-(3,5-dinitrophenyl)-1-(4-nitrobenzyl)-1H-tetrazole (48b). The title compounds were prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), 4-nitrobenzylamine (190 mg, 1.25 mmol, 2.50 equiv), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 30% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **48a** (128 mg, 0.34 mmol, 69% yield) was isolated as a white solid. R_f 0.16 (25% EtOAc/hexanes); mp 165-168 $^\circ\text{C}$; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 9.29 (d, J = 2.1 Hz, 2H), 9.13 (t, J = 2.1 Hz, 1H), 8.29 (dt, J = 8.8 Hz, 2.2 Hz, 2H), 7.64 (dt, J = 8.8 Hz, 2.2 Hz, 2H), 6.00 (s, 2H); $^{13}\text{C NMR}$ (125 MHz, CDCl_3) 162.5, 149.2, 148.7, 139.1, 130.8, 129.7, 126.8, 124.6, 120.2, 59.5; **FTIR** (cm^{-1}) (neat) 3200-2800, 1533, 1518, 1341, 919, 789, 722; **HRMS** (ESI-TOF) m/z : $[\text{M}-\text{H}]^-$ calcd for $\text{C}_{14}\text{H}_8\text{N}_7\text{O}_6$ 370.0542, found 370.0539.

Tetrazole **48b** (26.0 mg, 0.070 mmol, 14% yield) was isolated as a white solid; R_f 0.12 (50% EtOAc/hexanes); $^1\text{H NMR}$ (500 MHz, $\text{dms}-d_6$) δ 9.01 (t, J = 2.1 Hz, 1H), 8.92 (d, J = 2.1 Hz, 2H), 8.20 (d,



$J = 8.2$ Hz, 2H), 7.53 (d, $J = 8.8$ Hz, 2H), 5.97 (s, 2H); ^{13}C NMR (125 MHz, dmso-d_6) δ 152.0, 148.4, 147.4, 141.3, 129.9, 129.5, 126.4, 123.9, 120.9, 50.4. Due to the instability of tetrazole **48b**, melting point, infrared spectra, and HRMS could not be carried out.





2-Methyl-5-(3,5-dinitrophenyl)-2H-tetrazole (49a) and 1-methyl-5-(3,5-dinitrophenyl)-1H-tetrazole (49b). The title compounds were prepared according to the general procedure **B2** using 3,5-dinitrobenzonitrile (96.6 mg, 0.500 mmol, 1.00 equiv), dibutyltin oxide (18.7 mg, 0.075 mmol, 0.150 equiv), azidotrimethylsilane (0.986 mL, 0.750 mmol, 1.50 equiv), methylamine (0.625 mL, 1.25 mmol, 2.50 equiv, 2 M in THF), and 1,3-(2,2-dimethyl)propanedinitrite (0.093 mL, 0.800 mmol, 1.60 equiv) in toluene (4 mL, 1.5 mL for the first step + 2.5 mL for the second step). The crude mixture was purified by flash chromatography (300 mL 20% then 300 mL 50% EtOAc/hexanes) to separate the two tetrazole isomers. Tetrazole **49a** (108 mg, 0.43 mmol, 86% yield) was isolated as a white flaky as previously reported.⁷ R_f 0.69 (50% EtOAc/hexanes); mp 141-142 °C (litt. 144-145 °C);¹⁹ ^1H NMR (500 MHz, CDCl_3) δ 9.28 (d, $J = 2.1$ Hz, 2H), 9.10 (t, $J = 2.1$ Hz, 1H), 4.50 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) 161.9, 149.2, 131.1, 126.7, 119.9, 40.1.

Tetrazole **49b** (7.51 mg, 0.027 mmol, 6% yield) was isolated as an off-white solid. R_f 0.44 (50% EtOAc/hexanes); mp 193-197 °C; ^1H NMR (400 MHz, CDCl_3) δ 9.27 (t, $J = 2.0$ Hz, 1H), 9.02 (d, $J = 2.0$ Hz, 2H), 4.36 (s, 3H); ^{13}C NMR (125 MHz, $\text{CDCl}_3 + \text{CD}_3\text{OD}$) δ 151.2, 149.2, 128.6, 127.5, 121.1, 35.7; FTIR (cm^{-1}) (neat) 3200-2800, 1595, 1530, 1347, 730; HRMS (ESI-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_8\text{H}_7\text{N}_6\text{O}_4$ 251.0523, found 251.0515.



1,3-(2,2-Dimethyl)Propanedinitrite - 1H - CDCl3 - 500 MHz





1,3-(2,2-Dimethyl)propanedinitrite - ^{13}C - CDCl_3 - 125 MHz




2,2-diethylpropane-1,3-diyl dinitrite - 1H - CDCl3 - 300 MHz




2,2-diethylpropane-1,3-diyl dinitrite - ^{13}C - CDCl_3 - 125 MHz




cyclopropane-1,1-diylbis(methylene) dinitrite - 1H - CDCl3 - 300 MHz



cyclopropane-1,1-diylbis(methylene) dinitrite - ^{13}C - CDCl_3 - 75 MHz



3-(trimethylsilyl)prop-2-yn-1-amine - ^1H - CDCl_3 - 400 MHz



3-(trimethylsilyl)prop-2-yn-1-amine - ^{13}C - CDCl_3 - 100 MHz




— 107.461


— 86.686

— 32.530


— 0.090




2-(4-nitrobenzyl)isoindoline-1,3-dione - ¹H - CDCl₃ - 500 MHz





2-(4-nitrobenzyl)isoindoline-1,3-dione - ^{13}C - CDCl_3 125 MHz




— 167.922
— 147.722
— 143.431
— 134.496
— 131.997
— 129.516
— 124.127
— 123.767
— 41.018



4-nitrobenzylamine - ¹H - CDCl₃ - 500 MHz




4-nitrobenzylamine - ^{13}C CDCl $_3$ - 125 MHz




— 150.669
— 147.044

— 127.822
— 123.884

— 45.877




3,5-dimethylbenzonitrile - ¹H - CDCl₃ - 400 MHz



7.260
7.215

2.345





3,5-dimethylbenzonitrile - ^{13}C - CDCl_3 - 100 MHz



— 139.1387
— 134.7114
— 129.7779

— 119.3333
— 112.158



— 21.142



2-benzyl-5-(4-bromophenyl)-2H-tetrazole - ¹H - CDCl₃ - 400 MHz





2-benzyl-5-(4-bromophenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 125 MHz




1-benzyl-5-(4-bromophenyl)-1H-tetrazole- 1H - CDCl₃ - 300 MHz


7.655
7.625
7.463
7.434
7.370
7.366
7.355
7.347
7.156
7.145
7.142
7.132
7.130
7.125
— 5.613



1-benzyl-5-(4-bromophenyl)-1H-tetrazole - ^{13}C - CDCl_3 - 75 MHz



2-(5-(4-bromophenyl)-2H-tetrazol-2-yl)ethan-1-ol - ¹H - CDCl₃ - 500 MHz



2-(5-(4-bromophenyl)-2H-tetrazol-2-yl)ethan-1-ol - ^{13}C - CDCl_3 - 125 MHz

—164.51²



 $\sqrt{132.30^4}$
$$-128.4391$$

126.08


125.01.

— 60.54

—55.74




2-benzyl-5-(3-(trifluoromethyl)phenyl)-2H-tetrazole - 1H - CDCl3 - 400 MHz




2-benzyl-5-(4-(trifluoromethyl)phenyl)-2H-tetrazole - CDCl₃ - 100 MHz

164.41
133.22
132.02
131.70
131.37
131.05
130.14
129.55
129.20
128.55
128.35
128.00
127.04
127.00
126.96
126.92
125.30
123.96
123.93
123.89
123.85
122.59





57.122




2-benzyl-5-(4-(trifluoromethyl)phenyl)-2H-tetrazole - ^{19}F - CDCl_3 - 375 MHz

---62.822





1-benzyl-5-(4-(trifluoromethyl)phenyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz



1-benzyl-5-(4-(trifluoromethyl)phenyl)-1H-tetrazole - CDC13 - 100 MHz



153.599
133.555
132.299
132.022
131.699
131.366
130.022
129.466
129.188
128.211
128.177
128.143
128.107
127.299
125.999
125.955
125.911
125.889
124.855
124.791
122.088

51.854




1-benzyl-5-(4-(trifluoromethyl)phenyl)-1H-tetrazole - 19F - CDCl3 - 375 MHz

--62.933




2-(2-(5-(3-(trifluoromethyl)phenyl)-2H-tetrazol-2-yl)ethoxy)ethan-1-ol - ¹H -




8.37
8.30
8.28
7.69
7.67
7.60
7.58
7.56


4.86
4.84
4.83
4.09
4.08
4.07
3.68
3.67
3.66
3.64
3.63
3.59
3.58
3.57
2.66
2.64
2.63




2-(2-(5-(3-(trifluoromethyl)phenyl)-2H-tetrazol-2-yl)ethoxy)ethan-1-ol - ¹³C -




164.06
131.95
131.63
131.30
130.98
130.04
130.03
129.59
128.17
127.94
127.03
126.99
126.96
126.92
125.23
123.83
123.79
123.75
123.71
122.52
119.82
72.59
68.25
61.58
53.16




2-(2-(5-(3-(trifluoromethyl)phenyl)-2H-tetrazol-2-yl)ethoxy)ethan-1-ol - ^{19}F - CDCl_3 - 375 MHz



---62.85
—





4-(2-methyl-2H-tetrazol-5-yl)phenol - ¹H - acetone-d₆ - 400 MHz





4-(2-methyl-2H-tetrazol-5-yl)phenol - ^{13}C acetone- d_6 100 MHz

— 166.189
— 160.591
— 129.386
— 120.514
— 117.060


— 40.110



4-(1-methyl-1H-tetrazol-5-yl)phenol - ¹H - dmsO-d₆ - 400 MHz





4-(1-methyl-1H-tetrazol-5-yl)phenol ^{13}C - DMSO- d_6 - 100 MHz




2-benzyl-5-phenyl-2H-tetrazole - 1H - CDCl₃ - 400 MHz

8.162
8.156
8.143
7.477
7.463
7.412
7.384
7.368

5.803



2-benzyl-5-phenyl-1H-tetrazole - 100 MHz



165.54

133.46

130.40

129.10

129.03

128.94

128.46



127.45

126.96


56.89

1-benzyl-5-phenyl-1H-tetrazole - ¹H - CDCl₃ - 400 MHz


7.587
7.569
7.566
7.557
7.539
7.511
7.492
7.475
7.344
7.336
7.332
7.159
7.150
7.140
— 5.615




1-benzyl-5-phenyl-1H-tetrazole - 100 MHz




2-(3-chlorobenzyl)-5-phenyl-2H-tetrazole - ¹H - CDCl₃ - 400 MHz




2-(3-chlorobenzyl)-5-phenyl-2H-tetrazole - CDCl₃ - 100 MHz




1-(3-chlorobenzyl)-5-phenyl-1H-tetrazole - ¹H - CDCl₃ - 400 MHz




1-(3-chlorobenzyl)-5-phenyl-1H-tetrazole - CDCl₃ - 100 MHz




2-methyl-5-phenyl-2H-tetrazole - 1H - CDCl3 - 400MHz



2-methyl-5-phenyl-2H-tetrazole - ^{13}C CDCl₃ - 100 MHz



1-methyl-5-phenyl-1H-tetrazole - ¹H - CDCl₃ - 400 MHz



1-methyl-5-phenyl-1H-tetrazole - 13C

CDCl3 - 100 MHz

154.591



131.448

129.402


128.760

123.854

35.149



3-(5-phenyl-2H-tetrazol-2-yl)propan-1-ol - ¹H - CDCl₃ - 500 MHz




8.086
8.082
8.070
8.066
7.448
7.436
7.433
7.429
7.426
7.422
7.418
7.417
7.411



4.789
4.775
4.761

3.709
3.698
3.686
3.277



2.276
2.262
2.250
2.238
2.225





3-(5-phenyl-2H-tetrazol-2-yl)propan-1-ol - ^{13}C NMR - 125 MHz




3-(5-phenyl-1H-tetrazol-1-yl)propan-1-ol - 1H - CDCl3 - 500 MHz



3-(5-phenyl-1H-tetrazol-1-yl)propan-1-ol - ^{13}C - CDCl_3 - 125 MHz



4-(5-phenyl-2H-tetrazol-2-yl)butan-1-ol - 1H - CDCl3 - 500 MHz




8.140
8.136
8.124
8.121
7.499
7.493
7.482
7.470
7.467
7.463
7.455

4.718
4.704
4.689



3.720
3.707
3.695

2.202
2.187
2.172
2.157
2.143



1.798
1.665
1.653
1.646
1.640
1.637
1.634
1.628
1.622
1.609




4-(5-phenyl-2H-tetrazol-2-yl)butan-1-ol ¹³C - CDCl₃ - 125 MHz




4-(5-phenyl-1H-tetrazol-1-yl)butan-1-ol - ¹H - CDCl₃ - 500 MHz




4-(5-phenyl-1H-tetrazol-1-yl)butan-1-ol ¹³C - CDCl₃ - 125 MHz



— 154.4821
— 131.4116
— 129.4639
— 128.8991
— 124.2021
— 61.943
— 48.008
— 29.233
— 26.614





2-(2-(5-phenyl-2H-tetrazol-2-yl)ethoxy)ethan-1-ol - ¹H - CDCl₃ - 500 MHz





2-(2-(5-phenyl-2H-tetrazol-2-yl)ethoxy)ethan-1-ol ¹³C - CDCl₃ - 125 MHz



— 165.091
— 130.364
— 128.888
— 127.177
— 126.778
— 72.465
— 68.206
— 61.440
— 52.856




5-phenyl-2-(3-(trimethylsilyl)prop-2-yn-1-yl)-2H-tetrazole - 1H - CDCl₃ - 500



5-phenyl-2-(3-(trimethylsilyl)prop-1-yn-1-yl)-2H-tetrazole - ¹³C - CDCl₃ - 125




5-phenyl-1-(3-(trimethylsilyl)prop-2-yn-1-yl)-1H-tetrazole - ¹H - CDCl₃ - 500





7.887
7.885
7.881
7.876
7.872
7.868
7.609
7.608
7.599
7.595
7.591
7.588
7.582
7.579
7.576
7.564

— 5.218


— 0.135



5-phenyl-1-(3-(trimethylsilyl)prop-2-yn-1-yl)-1H-tetrazole - ^{13}C - CDCl_3 - 125



2-isopropyl-5-phenyl-2H-tetrazole - 1H - CDCl₃ - 400 MHz



2-isopropyl-5-phenyl-2H-tetrazole CDCl₃ - 100 MHz

— 164.878

130.232



128.943

127.846

126.917

— 56.656

— 22.347





1-isopropyl-5-phenyl-1H-tetrazole - ¹H - CDCl₃ - 400 MHz

7.623
7.619
7.605
7.599
7.590
7.580
7.576
7.557

4.822
4.806
4.789
4.772
4.756
4.739
4.722

1.642
1.625



1-isopropyl-5-phenyl-1H-tetrazole ¹³C CDCl₃ - 100 MHz

— 153.71

— 131.259



— 129.402

— 129.021

— 124.521

— 51.257

— 23.092





2-cyclopentyl-5-phenyl-2H-tetrazole - 1H - CDCl3 - 400 MHz


8.156
8.152
8.137
8.133
7.499
7.492
7.477
7.459
7.444

5.297
5.281
5.265
5.249
5.232

2.309
2.293
2.276
2.260
2.006
1.994
1.984
1.966
1.803
1.790
1.785
1.774
1.764
1.762
1.756



2-cyclopentyl-5-phenyl-2H-tetrazole - CDCl₃ - 100 MHz





1-cyclopentyl-5-phenyl-1H-tetrazole - 1H - CDCl3 - 400 MHz


7.649
7.645
7.631
7.626
7.571
7.554

4.897
4.880
4.862
4.845
4.828


2.210
2.195
2.178
2.161
2.088
2.075
2.066
2.050
1.757
1.742
1.739
1.729
1.717





1-cyclopentyl-5-phenyl-1H-tetrazol-1-yl - CDCl₃ - 100 MHz





154.242
131.200
129.336
129.137
124.620
59.597
34.040
24.820




2-adamantan-1-yl-5-phenyl-2H-tetrazole - ¹H - CDCl₃ - 500 MHz



2-adamantan-1-yl-5-phenyl-2H-tetrazole ¹³C - CDCl₃ - 125 MHz





5-phenyl-2-triphenylmethyl-2H-tetrazole - 1H - CDCl₃ - 400 MHz




5-phenyl-2-triphenylmethyl-2H-tetrazole ¹³C - CDCl₃ - 100 MHz

164.155
141.527
130.448
130.376
128.899
128.457
127.909
127.704
127.181
83.247



2-benzyl-5-(5-chlorothiophen-2-yl)-2H-tetrazole - 1H - CDCl₃ - 400 MHz



2-benzyl-5-(5-chlorothiophen-2-yl)-1,2,4-triazole - ¹³C - CDCl₃ - 100 MHz

— 160.810

133.150

133.000

129.209

129.191



128.567

127.700

127.255

127.180



— 57.029



1-benzyl-5-(5-chlorothiophen-2-yl)-1H-tetrazole - ¹H - CDCl₃ - 400 MHz

7.386
7.368
7.208
7.198
7.165
7.161
7.145
6.961
6.951



— 5.730





1-benzyl-5-(5-chlorothiophen-2-yl)-1H-tetrazole - ¹³C - CDCl₃ - 100 MHz

149.06
136.08
133.35
129.69
129.52
129.08
127.58
126.86
122.70



51.634





3-(5-(5-chlorothiophen-2-yl)-2H-tetrazol-2-yl)propan-1-ol - ¹H - CDCl₃ - 500 M





3-(5-(5-chlorothiophen-2-yl)-2H-tetrazol-2-yl)propan-1-ol - ¹³C - CDCl₃ - 125 °C




3-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)propan-1-ol - ¹H - CDCl₃ - 400 M




3-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)propan-1-ol - ¹³C - CDCl₃ - 100 °C




8-(5-(5-chlorothiophen-2-yl)-2H-tetrazol-2-yl)octan-1-ol - 1H - CDCl3 - 500 MH





8-(5-(5-chlorothiophen-2-yl)-2H-tetrazol-2-yl)octan-1-ol - ^{13}C - CDCl_3 - 125 M





— 160.14
— 132.63
— 127.62
— 127.07
— 126.95
— 62.61
— 53.25
— 32.57
— 29.18
— 29.07
— 28.76
— 26.18
— 25.57




8-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)octan-1-ol - ¹H - CDCl₃ - 500 MH




8-(5-(5-chlorothiophen-2-yl)-1H-tetrazol-1-yl)octan-1-ol - ^{13}C - CDCl_3 - 125 M




4-(2-phenethyl-2H-tetrazol-5-yl)pyridine - ¹H - CDCl₃ - 400 MHz



4-(2-phenethyl-2H-tetrazol-5-yl)pyridine ¹³C - CDCl₃ - :




4-(1-phenethyl-1H-tetrazol-5-yl)pyridine - 1H - CDCl3 - 400 MHz




4-(1-phenethyl-1H-tetrazol-5-yl)pyridine ¹³C - CDCl₃ - 100 MHz

153.032
150.673
135.898
131.843
129.194
128.797
127.749
122.730



2-(2-benzyl-2H-tetrazol-5-yl)pyridine - ¹H - CDCl₃ - 400 MHz



2-(2-benzyl-2H-tetrazol-5-yl)pyridine - ^{13}C - CDCl_3 - 75 MHz

—165.072

—150.343

—146.797

—137.129

—133.136



—129.053

—128.597


—124.885

—122.505

—57.146





2-(1-benzyl-1H-tetrazol-5-yl)pyridine - 1H - CDCl₃ - 500 MHz





2-(1-benzyl-1H-tetrazol-5-yl)pyridine - ^{13}C - CDCl_3 - 125 MHz

151.697
149.413
144.926
137.582
134.915
128.828
128.514
128.407
125.562
124.677

52.706



Ethyl 2-(2-benzyl-2H-tetrazol-5-yl)acetate - ¹H - CDCl₃ - 400 MHz



Ethyl 2-(2-benzyl-2H-tetrazol-5-yl)acetate - ¹³C - CDCl₃ - 75 MHz

— 168.380

— 160.622

— 133.261

— 129.158

— 129.120



— 128.495

— 61.720


— 56.926

— 32.007



— 14.181




Ethyl 2-(1-benzyl-1H-tetrazol-5-yl)acetate - ¹H - CDCl₃ - 500 MHz



Ethyl 2-(1-benzyl-1H-tetrazol-5-yl)acetate - ^{13}C - CDCl_3 - 125 MHz



2-(2-benzyl-2H-tetrazol-5-yl)ethan-1-ol - ¹H - CDCl₃ - 400 MHz



2-(2-benzyl-2H-tetrazol-5-yl)ethanol - ^{13}C - CDCl_3 - 100 MHz

— 165.038

— 133.241

— 129.106



— 129.079

— 128.505


— 60.260

— 56.772

— 28.887



2-(4-bromophenethyl)-5-(3,5-dinitrophenyl)-2H-tetrazole - ¹H - CDCl₃ - 400 MHz



2-(4-bromophenethyl)-5-(3,5-dinitrophenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 100 MHz

— 161.797

— 149.223

— 134.942

— 132.238

— 131.103

— 130.424


— 126.757

— 121.590


— 119.961

— 54.552


— 35.053



2-(4-bromophenethyl)-5-(2,4-dimethoxyphenyl)-2H-tetrazole - ¹H - CDCl₃ - 400 M





7.889
7.868
7.406
7.385
7.051
7.030
6.612
6.606
6.585
6.581
6.575
4.859
4.840
4.821
3.900
3.850
3.333
3.314
3.295




2-(4-bromophenethyl)-5-(2,4-dimethoxyphenyl)-2H-tetrazole - ¹³C - CDCl₃ - 100


163.278
162.624
158.770
135.664
131.943
131.688
130.511
121.118
109.428
105.146
99.221
56.093
55.549
53.752
35.187



1-(4-bromophenethyl)-5-(2,4-dimethoxyphenyl)-1H-tetrazole - ¹H - CDCl₃ - 400 M





7.285
7.264
7.014
6.993
6.770
6.750
6.556
6.551
6.535
6.530
6.516
6.511
4.460
4.442
4.425
3.872
3.770
3.118
3.101
3.083




1-(4-bromophenethyl)-5-(2,4-dimethoxyphenyl)-1H-tetrazole - ¹³C - CDCl₃ - 100 °C



— 163.658
 — 157.870
 — 153.009
 — 135.767
 — 132.798
 — 131.918
 — 130.371
 — 121.153
 — 105.422
 — 99.029
 — 55.887
 — 55.772
 — 49.004
 — 35.378





-7.867
 -7.863
 -7.847
 -7.843
 -7.741
 -7.739
 -7.721
 -7.719
 -7.444
 -7.442
 -7.425
 -7.423
 -7.406
 -7.404
 -7.337
 -7.333
 -7.317
 -7.314
 -7.298
 -7.294
 -4.821
 -4.802
 -4.792
 -4.783
 -4.764
 -2.333
 -2.325
 -2.301
 -2.294
 -2.097
 -2.088
 -2.067
 -2.058
 -2.037
 -2.028
 -1.998
 -1.993
 -1.982
 -1.973
 -1.957
 -1.948
 -1.941
 -1.787
 -1.778
 -1.764
 -1.755
 -1.746
 -1.552
 -1.529
 -1.521
 -1.513
 -1.497
 -1.489
 -1.481
 -1.457
 -1.411
 -1.388
 -1.380
 -1.349





5-(2-bromophenyl)-2-cyclohexyl-2H-tetrazole - ^{13}C - CDCl_3 - 100 MHz



5-(2-bromophenyl)-1-cyclohexyl-1H-tetrazole - ¹H - CDCl₃ - 400 MHz





5-(2-bromophenyl)-1-cyclohexyl-1H-tetrazole - ¹³C - CDCl₃ - 100 MHz



2-phenethyl-5-(2-nitrophenyl)-2H-tetrazole - 1H - CDCl3 - 400 MHz

7.936
7.933
7.917
7.914
7.883
7.880
7.863
7.860
7.711
7.707
7.692
7.688
7.673
7.669
7.642
7.639
7.623
7.619
7.604
7.600
7.325
7.322
7.318
7.305
7.301
7.286
7.264
7.260
7.257
7.248
7.242
7.235
7.227
7.224
7.177
7.174
7.157
4.903
4.885
4.866
3.370
3.351
3.333





2-phenethyl-5-(2-nitrophenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 100 MHz


— 161.405
— 149.071
— 136.288
— 132.444
— 131.191
— 131.064
— 128.908
— 128.722
— 127.278
— 124.227
— 121.575

— 54.574


— 35.703



1-phenethyl-5-(2-nitrophenyl)-1H-tetrazole - 1H - CDCl3 - 500 MHz




1-phenethyl-5-(2-nitrophenyl)-1H-tetrazole - 13C - CDC13 - 125 MHz



152.483
147.573
136.548
133.972
132.771
132.314
129.111
128.921
127.420
125.336
119.791



— 49.447

— 35.793





3-(2-allyl-2H-tetrazol-5-yl)pyridine - 1H - CDCl3 - 400 MHz


9.370
9.367
8.712
8.708
8.700
8.696
8.429
8.424
8.420
8.409
8.405
8.400
7.438
7.436
7.425
7.424
7.418
7.416
7.406
7.404
6.180
6.164
6.155
6.148
6.139
6.121
6.112
6.105
6.096
6.080
5.448
5.421
5.420
5.407
5.405
5.293
5.290
5.286
5.277
5.274
5.271



3-(2-allyl-2H-tetrazol-5-yl)pyridine - CDCl₃ - 100 MHz





3-(1-allyl-1H-tetrazol-5-yl)pyridine - 1H - CDCl₃ - 400 MHz




3-(1-allyl-1H-tetrazol-5-yl)pyridine - ^{13}C CDCl₃ - 100 MHz

152.507
152.328
149.070
136.493
130.386
124.070
120.647
120.320


50.417




3-(2-(2-bromo-4,5-dimethoxyphenethyl)-2H-tetrazol-5-yl)-2-fluoropyridine - 1H





3-(2-(2-bromo-4,5-dimethoxyphenethyl)-2H-tetrazol-5-yl)-2-fluoropyridine - ¹³C




161.208
160.029
159.941
159.254
149.416
149.298
149.021
148.641
140.554
140.534
127.511
121.877
121.841
115.833
114.436
113.364
111.206
110.987
56.286
56.111
53.029
35.846



3-(2-(2-bromo-4,5-dimethoxyphenethyl)-2H-tetrazol-5-yl)-2-fluoropyridine - ^{19}F




3-(1-(2-bromo-4,5-dimethoxyphenethyl)-1H-tetrazol-5-yl)-2-fluoropyridine - 1H



8.374
8.362
7.558
7.554
7.539
7.535
7.531
7.517
7.512
7.235
7.231
7.223
7.218
7.212
7.205
7.200
6.683
6.104

4.754
4.738
4.721

3.792
3.673
3.205
3.189
3.172





3-(1-(2-bromo-4,5-dimethoxyphenethyl)-1H-tetrazol-5-yl)-2-fluoropyridine - ¹³C

160.320
157.934
150.905
150.753
150.104
150.041
149.019
148.689
142.497
142.470



127.032
121.765
121.720
115.573
114.054
113.021
107.729
107.426

56.312
56.155
47.882
47.822

36.477



3-(1-(2-bromo-4,5-dimethoxyphenethyl)-1H-tetrazol-5-yl)-2-fluoropyridine - ^{19}F



1-(2-(3-isopropoxypropyl)-2H-tetrazol-5-yl)isoquinoline - ¹H - CDCl₃ - 400 MHz



8.858
8.837
8.682
8.668
7.947
7.926
7.846
7.832
7.811
7.809
7.794
7.791
7.773
7.771
7.738
7.736
7.717
7.700
7.697

4.925
4.908
4.891

3.396
3.389
3.381
3.375
3.366
3.360
3.351
3.335



2.203
2.187
2.171
2.155
2.139

0.974
0.959



1-(2-(3-isopropoxypropyl)-2H-tetrazol-5-yl)isoquinoline - ¹³C - CDCl₃ - 100 MHz

— 152.007
 — 144.680
 — 141.853
 — 136.996
 — 131.188
 — 129.113
 — 127.835
 — 127.245
 — 127.117
 — 123.267
 — 71.694
 — 64.298
 — 46.783
 — 30.461
 — 21.995




1-(1-(3-isopropoxypropyl)-1H-tetrazol-5-yl)isoquinoline - 1H - CDCl₃ - 400 MHz


9.176
9.155
8.742
8.728
7.925
7.905
7.797
7.783
7.777
7.774
7.757
7.740
7.737
7.729
7.725
7.708
7.705
7.690
7.687

4.936
4.918
4.901
3.612
3.597
3.582
3.567
3.552
3.536
3.524
3.510
3.495
2.422
2.405
2.390
2.375
2.358

1.160
1.145





30b




1-(1-(3-isopropoxypropyl)-1H-tetrazol-5-yl)isoquinoline - ¹³C - CDCl₃ - 100 MHz



— 165.052
 — 146.555
 — 142.638
 — 137.134
 — 130.641
 — 128.570
 — 127.315
 — 127.165
 — 127.024
 — 122.688
 — 71.992
 — 64.203
 — 51.077
 — 30.129
 — 22.173





5-benzhydryl-2-(2,2-dimethoxyethyl)-2H-tetrazole - ¹H - CDCl₃ - 500 MHz





5-benzhydryl-2-(2,2-dimethoxyethyl)-2H-tetrazole - ^{13}C - CDCl_3 - 100 MHz




2-(5-benzyl-2H-tetrazol-2-yl)-N,N-diethylethan-1-amine - ^1H - CDCl_3 - 400 MHz



2-(5-benzyl-2H-tetrazol-2-yl)-N,N-diethylethan-1-amine - ^{13}C - CDCl_3 - 100 MHz



2-(5-benzyl-1H-tetrazol-1-yl)-N,N-diethylethan-1-amine - ^1H - CDCl_3 - 400 MHz




7.335
7.318
7.299
7.283
7.265
7.260
7.176
7.158


4.358
4.149
4.133
4.118

2.736
2.720
2.705
2.458
2.441
2.423
2.405


0.887
0.869
0.851





2-(5-benzyl-1H-tetrazol-1-yl)-N,N-diethylethan-1-amine - ^{13}C - CDCl_3 - 100 MHz





— 154.271
 \ 134.367
 / 129.222
 \ 128.527
 / 127.718
 — 52.720
 \ 47.581
 / 46.599
 — 29.580
 — 11.924




2-benzyl-5-methyl-2H-tetrazole - ¹H - CDCl₃ - 500 MHz



2-benzyl-5-methyl-2H-tetrazole - ^{13}C - CDC13 - 125 MHz




1-benzyl-5-methyl-1H-tetrazole - ¹H - CDCl₃ - 500 MHz




7.375
7.371
7.362
7.361
7.203
7.198
7.187

— 5.496

— 2.445



1-benzyl-5-methyl-1H-tetrazole - ¹³C



— 151.763

133.231


129.417

129.119



127.594

— 51.027

— 9.172



4-((5-cyclopropyl-2H-tetrazol-2-yl)methyl)pyridine - ¹H - CDCl₃ - 400 MHz



4-((5-cyclopropyl-2H-tetrazol-2-yl)methyl)pyridine - ¹³C - CDCl₃ - 125 MHz

— 169.678



— 150.608

— 142.165



— 122.573

— 55.105


8.858
6.682



4-((5-cyclopropyl-1H-tetrazol-1-yl)methyl)pyridine - 1H - CDCl3 - 400 MHz



4-((5-cyclopropyl-1H-tetrazol-1-yl)methyl)pyridine - ^{13}C - CDCl_3 - 100 MHz



— 157.458

— 150.870


— 142.529

— 121.831



— 49.289

— 9.169



— 4.107




2-phenethyl-5-(3,5-dimethylphenyl)-2H-tetrazol-1H - CDCl₃ 500 MHz




2-phenethyl-5-(3,5-dimethylphenyl)-2H-tetrazole - CDCl₃ - 125 MHz




1-phenethyl-5-(3,5-dimethylphenyl)-1H-tetrazole - CDCl₃ 400 MHz



7.238
7.231
7.223
7.120
6.962
6.956
6.954
6.948
6.939
6.803
4.587
4.569
4.552
3.275
3.258
3.240
2.307



1-phenethyl-5-(3,5-dimethylphenyl)-1H-tetrazole
CDCl₃ - 100 MHz




155.222
138.870
136.517
132.747
129.047
128.861
127.338
126.492
123.626


49.249

36.223


21.275





2-phenethyl-5-phenyl-2H-tetrazole - ¹H - CDCl₃ - 400 MHz




2-phenethyl-5-phenyl-2H-tetrazole



1-phenethyl-5-phenyl-1H-tetrazole - ¹H - CDCl₃ - 500 MHz




1-phenethyl-5-phenyl-1H-tetrazole - ^{13}C - CDC13 - 125 MHz




— 154.838
— 136.200
— 131.072
— 129.093
— 128.934
— 128.732
— 128.699
— 127.357
— 123.839

— 49.217


— 36.085



5-(3-bromophenyl)-2-phenethyl-2H-tetrazole - ¹H - CDCl₃ - 400 MHz




5-(3-bromophenyl)-2-phenethyl-2H-tetrazole





100 MHz
163.94
136.43
133.36
130.59
129.92
129.50
129.00
128.75
127.37
125.47
123.09

54.459



35.828




5-(3-bromophenyl)-1-phenethyl-1H-tetrazole - 1H - CDCl₃ - 500 MHz




5-(3-bromophenyl)-1-phenethyl-1H-tetrazole - ^{13}C - CDCl_3 - 125 MHz



2-phenethyl-5-(3-nitrophenyl)-2H-tetrazole - ¹H - CDCl₃ - 400 MHz



2-phenethyl-5-(3-nitrophenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 100 MHz



— 163.353

— 148.847

— 136.307

— 132.593

— 130.187

— 129.337

— 129.047

— 128.762


— 127.455

— 124.952



— 121.997

— 54.629



— 35.814




1-phenethyl-5-(3-nitrophenyl)-1H-tetrazole - 1H - CDCl₃ - 500 MHz




1-phenethyl-5-(3-nitrophenyl)-1H-tetrazole - ^{13}C - CDCl_3 - 125 MHz



2-phenethyl-5-(4-nitrophenyl)-2H-tetrazole - ¹H - CDCl₃ - 500 MHz



2-phenethyl-5-(4-nitrophenyl)-2H-tetrazole



— 163.304

— 148.963

136.254

133.417

129.019

128.732


127.750

127.438



124.333

— 54.624


— 35.785



1-phenethyl-5-(4-nitrophenyl)-1H-tetrazole - 1H - CDCl₃ - 500 MHz



1-phenethyl-5-(4-nitrophenyl)-1H-tetrazole




13C
153.469
149.308
135.992
130.056
130.023
129.239
128.830
127.805
124.155


CDC13 - 125 MHz

49.828


36.393




5-(3,5-dinitrophenyl)-2-(1-phenylethyl)-2H-tetrazole - 1H - CDCl₃ - 500 MHz





5-(3,5-dinitrophenyl)-2-(1-phenylethyl)-2H-tetrazole - ¹³C - CDCl₃ - 125 MHz




— 161.718
— 149.162
— 138.192
— 131.394
— 129.285
— 126.890
— 126.813
— 119.852
— 64.636
— 21.095



2-benzyl-5-(3,5-dimethylphenyl)-2H-tetrazole 1H, CDCl3 - 500 MHz



2-benzyl-5-(3,5-dimethylphenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 125 MHz



— 165.787

138.603

133.536

132.090

129.092

128.988


128.398

127.163


124.714

— 56.841

— 21.330




1-benzyl-5-(3,5-dimethylphenyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz




7.366
7.362
7.352
7.348
7.198
7.191
7.178
7.172
7.164

5.588

2.332




1-benzyl-5-(3,5-dimethylphenyl)-1H-tetrazole - ^{13}C - CDCl_3 - 125 MHz




— 155.065
— 139.069
— 134.319
— 133.047
— 129.246
— 128.879
— 127.470
— 126.741
— 123.588

— 51.513



— 21.319



2-benzyl-5-(3-bromophenyl)-2H-tetrazole - 1H - CDCl₃ - 500 MHz





2-benzyl-5-(3-bromophenyl)-2H-tetrazole - 133.00 MHz




1-benzyl-5-(3-bromophenyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz

7.729
7.725
7.721
7.695
7.675
7.520
7.517
7.514
7.500
7.498
7.494
7.388
7.375
7.369
7.362
7.358
7.350
7.184
7.177
7.165
5.616




1-benzyl-5-(3-bromophenyl)-1H-tetrazole




153.5351
134.5351
133.7133
132.0121
130.8041
129.4410
129.1341
127.5143
127.3901
125.8091
123.2830

MHz


51.744



2-benzyl-5-(3-nitrophenyl)-2H-tetrazole - 1H - CDCl3 - 500 MHz



2-benzyl-5-(3-nitrophenyl)-2H-tetrazole - ^{13}C - CDC13 - 125 MHz



— 163.681

— 148.742

133.042
132.616

130.118

129.288


129.230

128.638


124.935

121.970


— 57.248



1-benzyl-5-(3-nitrophenyl)-1H-tetrazole - 1H - CDCl₃ - 500 MHz




1-benzyl-5-(3-nitrophenyl)-1H-tetrazole



¹³C - CDCl₃ 125 MHz



Chemical Shift (ppm)
152.789
148.475
134.924
133.215
130.686
129.584
129.348
127.348
126.092
125.610
123.761

52.085





2-benzyl-5-(4-nitrophenyl)-1H-tetrazol-4-yl 500 MHz

8.313
7.452
7.448
7.444
7.439
7.436
7.433
7.418
7.411
7.407
7.402
7.400
7.397
7.392
7.390
7.387
7.386
7.384
7.377
7.374
5.838





2-benzyl-5-(4-nitrophenyl)-2H-tetrazole 125 MHz




1-benzyl-5-(4-nitrophenyl)-1H-tetrazole
500 MHz

8.361
8.356
8.354
8.345
8.339
8.337
8.334
7.804
7.799
7.795
7.785
7.781
7.777
7.381
7.378
7.372
7.367
7.150
7.143
7.135
7.131
5.678




1-benzyl-5-(4-nitrophenyl)-1H-tetrazole ^{13}C - CDCl_3 125 MHz





153.070
149.570
133.394
130.176
130.000
129.613
129.344
127.116
124.436

51.974




2-benzyl-5-(3,5-dinitrophenyl)-2H-tetrazole - 1H - CDCl₃ - 400 MHz


9.291
9.286
9.105
9.100
9.095
7.476
7.462
7.459
7.422
7.415
7.408
7.405
5.875



2-benzyl-5-(3,5-dinitrophenyl)-2H-tetrazole - ^{13}C - 100 MHz



— 162.107
— 149.154
132.643
131.163
129.539
129.359
128.772
126.781
119.903
— 57.623





1-benzyl-5-(3,5-dinitrophenyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz


9.167
9.162
9.158
8.831
8.826

7.425
7.408
7.260
7.247
7.243
7.228

5.797




1-benzyl-5-(3,5-dinitrophenyl)-1H-tetrazole - 100 MHz




151.129
149.012
132.523
129.932
129.845
128.821
127.487
127.350
121.020


52.695




5-(3,5-dinitrophenyl)-2-(1-phenylethyl)-2H-tetrazole - 1H - CDCl₃ - 500 MHz




5-(3,5-dinitrophenyl)-2-(1-phenylethyl)-2H-tetrazole - ¹³C - CDCl₃ - 125 MHz




—161.72
—149.16
—138.19
—131.39
—129.28
—126.89
—126.81
—119.85
—64.64
—21.09



5-(3,5-dinitrophenyl)-1-(1-phenylethyl)-1H-tetrazole - 1H - CDCl₃ - 500 MHz




5-(3,5-dinitrophenyl)-1-(1-phenylethyl)-1H-tetrazole - ¹³C - CDCl₃ - 125 MHz




151.000
148.919
138.891
129.951
129.556
129.195
127.957
126.065
120.913

— 60.598


— 23.444




5-(3,5-dinitrophenyl)-2-(4-methoxybenzyl)-2H-tetrazole - ¹H - CDCl₃ - 500 MHz




5-(3,5-dinitrophenyl)-2-(4-methoxybenzyl)-2H-tetrazole ¹³C - CDCl₃ - 125 MHz




162.008
160.488
149.107
131.216
130.391
126.743
124.658
119.838
114.639
57.216
55.458




5-(3,5-dinitrophenyl)-1-(4-methoxybenzyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz



5-(3,5-dinitrophenyl)-1-(4-methoxybenzyl)-1H-tetrazole ¹³C - CDCl₃ - 125 MHz




— 160.613
— 150.968
— 148.971
— 128.996
— 128.895
— 127.601
— 124.292
— 120.974
— 115.190
— 55.555
— 52.395




230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 ppm


5-(3,5-dinitrophenyl)-2-(4-nitrobenzyl)-2H-tetrazole - 1H - CDCl₃ - 400 MHz




5-(3,5-dinitrophenyl)-2-(4-nitrobenzyl)-2H-tetrazole ¹³C - CDCl₃ - 125 MHz



— 162.508
— 149.223
— 148.687
— 139.106
— 130.731
— 129.738
— 126.839
— 124.630
— 120.204
— 56.475





5-(3,5-dinitrophenyl)-1-(4-nitrobenzyl)-1H-tetrazole - 1H - DMSO-d6 - 500 MHz




5-(3,5-dinitrophenyl)-1-(4-nitrobenzyl)-1H-tetrazole - ^{13}C - DMSO- d_6 - 125 MHz

151.961
148.412
147.406
141.306
129.907
129.466
126.355
123.886
120.901

50.384



2-methyl-5-(3,5-dinitrophenyl)-2H-tetrazole - 1H - CDCl₃ - 500 MHz



2-methyl-5-(3,5-dinitrophenyl)-2H-tetrazole - ^{13}C - CDCl_3 - 125 MHz

— 161.885



— 149.180

— 131.118

— 126.692

— 119.896



— 40.145



1-methyl-5-(3,5-dinitrophenyl)-1H-tetrazole - 1H - CDCl₃ - 400 MHz

9.275
9.270
9.265
9.024
9.019

4.359



1.00
2.04

3.00

11

10

9

8

7

6

5

4

3

2

1

ppm

1-methyl-5-(3,5-dinitrophenyl)-1H-tetrazole - ^{13}C CDCl₃+MeOD - 125 MHz

